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Abstract 
Sulochanadevi Baskaran 
 
STRUCTURE AND REGULATION OF  
YEAST GLYCOGEN SYNTHASE 
 
Glycogen is a major energy reserve in most eukaryotes and its rate of 
synthesis is controlled by glycogen synthase. The activity of eukaryotic glycogen 
synthase is regulated by the allosteric activator glucose-6-phosphate, which can 
overcome the inhibitory effects of phosphorylation. The effects of phosphorylation 
and glucose-6-phosphate on glycogen synthase are mediated by a cluster of six 
arginines located within a stretch of 12 amino acids near the C-terminus of the 
enzyme’s polypeptide chain. We studied isoform-2 of yeast glycogen synthase as 
a model to study the structural and molecular mechanisms that underlie the 
regulation of the eukaryotic enzymes and our primary tools of investigation were 
macromolecular X-ray crystallography, site-directed mutagenesis, intein-
mediated peptide ligation and enzyme assays. We have solved the tetrameric 
structure of the yeast enzyme in two different activity states; the resting enzyme 
and the activated state when complexed with glucose-6-phosphate. Binding of 
glucose-6-phosphate to glycogen synthase induces large conformational 
changes that free the active site of the subunits to undergo conformational 
changes necessary to catalyze the reaction. Further, using site directed 
mutagenesis and intein-mediated peptide ligation to create specific 
phosphorylation states of the enzyme we were able to define specific roles for 
vii 
 
the arginine residues that mediate the regulatory effects of phosphorylation and 
glucose-6-phosphate activation. Based on these studies, we propose a three 
state structural model for the regulation of the enzyme, which relate the observed 
conformational states to specific activity levels. In addition to these regulatory 
studies, we have also solved the structure of the enzyme complexed with UDP 
and with substrate analogs, which provide detailed insight into the catalytic 
mechanism of the enzyme and the ability of glycogen synthase to remain tightly 
bound to its substrate glycogen. 
 
 
                Thomas D. Hurley, Ph.D., Chair 
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INTRODUCTION 
A. Glycogen 
1. Structure of glycogen 
 Glycogen, a branched polymer of glucose serves as one of the major 
repositories of carbon and energy in eukaryotes. The linear polymerization of 
glycogen is through α-1,4 glycosidic bonds and branch points are introduced by 
α-1,6 linkages, on an average for every ten to thirteen residues. Glycogen 
molecules are spherical in shape, organized in concentric tiers and the structure 
is an example of biological fractal where any substructure of the particle is 
representative of the whole structure1,2. It is theorized that the matured glycogen 
molecule contains 12 tiers, with approximately 55,000 glucose residues and a 
molecular weight on the order of 107 daltons. The spherical structure of glycogen 
gives a homogeneously symmetrical shape and enables the maximal storage of 
glucose in the minimal volume while exposing the maximal number of terminal 
glucose residues on the outer surface. The structural organization also provides 
stability by facilitating formation of the maximum number of hydrogen bonds 
between the glucose residues within the same polymer. The fractal organization 
of glycogen facilitates the rapid synthesis and degradation, allowing quick 
release of the stored fuel and fast recovery upon depletion. In addition to 
glucose, glycogen also contains minor constituents like glucosamines3 and 
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phosphates4, the later influences the branching characteristics of glycogen and is 
implicated in Lafora disease5. 
 
Figure 1. Structutre of glycogen.  
The spherical glycogen molecule is proposed to be composed of twelve 
concentric tires and is formed by linear polymerization via α-1,4 linkages and 
branch points through α-1,6 linkages. Figure adapted from Biophys J . 77, 1327-
1332, (1999). 
 
 
2. Biosynthesis and degradation  
 The biosynthetic pathway of glycogen synthesis is highly conserved 
across eukaryotic species (Figure 2). In cells, synthesis from glucose begins with 
its conversion to UDP-glucose through the sequential action of hexokinase, 
phosphoglucomutase and UDP-glucose pyrophosphorylase. Glucose 
polymerization is initiated by glycogenin in an autocatalytic manner6,7 where 
glucose residues are transferred from the glucose donor UDP-glucose to a 
conserved tyrosine residue in the protein, via covalent O-glycosidic linkages8,9. 
Further polymerization of glucose to about 10 residues through α −1,4 glycosidic 
linkage is required before glycogen synthase (GS) and the branching enzyme 
(BE) take over. GS catalyzes the linear polymerization of glucose by transferring 
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glucose residues from an activated sugar donor to the non-reducing 4’ end of the 
glycogen chain. BE is an amylo (1,4→1,6) – transglycosylase and transfers the 
terminal chain segment of approximately seven glycosyl residues to the C6 
hydroxyl group of a glucose residue on the same or another chain10. 
The two enzymes involved in the degradation of glycogen are glycogen 
phosphorylase (GPh) and the debranching enzyme (DBE). GPh catalyzes the 
sequential phosphorolysis of the α −1,4 glycosidic linkages generating glucose-1-
phosphate and uses pyridoxal phosphate as the cofactor. When the linear chain 
is less than five residues from a branch point (limit branch), DBE comes into play. 
The N-domain α −1,4 transglycosylase activity of DBE transfers the limit branch 
of glycogen to the 4’ end of another branch facilitating further hydrolysis by 
GPh11. The C-domain α −1,6 glucosidase activity of DBE hydrolyses the α −1,6  
linkages at the branch points11.   
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Figure 2. Pathway for the biosynthesis and degradation of glycogen. 
Synthesis of glycogen polymer involves the activity of the glycogenin, glycogen 
synthase and branching enzyme. Degradation of the polymer is mediated by 
glycogen phosphorylase and debranching enzyme. 
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3. Physiological role of glycogen in mammals  
 Glycogen serves as the primary reserve of energy in most animals and 
fungi. Though the biosynthetic pathway of synthesis is highly conserved, the 
nutritional and hormonal stimuli that regulate the synthesis and degradation of 
glycogen are different in these organisms. A detailed discussion of the all the 
regulatory pathways is beyond the scope of this thesis session and a brief 
overview of the regulation is provided.  
 In higher eukaryotes including mammals, glycogen is synthesized at times 
of nutritional abundance12-14. The two major tissues or organ systems that serve 
as the glycogen stores in the higher eukaryotes are skeletal muscle and liver. 
Other organs like the brain, adipose, kidney and pancreas are also capable of 
synthesizing glycogen. Insulin stimulated glycogen synthesis accounts for up to 
30% in liver and between 30-90% in muscle of postprandial carbohydrate 
disposal. Depletion of liver and muscle glycogen is observed in type 2 diabetics 
and impairment of insulin stimulated glycogen synthesis is detectable during the 
early onset of diabetes and in the pathogenesis of insulin resistant type 2 
diabetes15. Deficiency in the enzymes involved in glycogen metabolism lead to 
glycogen storage disease (GSD), which affect the liver, muscle or both tissues.  
  In the skeletal muscle, glycogen provides energy for muscular contraction 
in the generation of glucose-6-phosphate for entry into glycolysis as a means for 
ATP production. The liver glycogen plays a pivotal role in glucose homoeostasis 
– maintaining circulating blood glucose levels during fasting. The muscle and 
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liver tissues express different forms of glucose transporters, hexokinases, GPh 
and GS, and the regulation of glycogen metabolism is slightly different in both 
these tissues, reflecting their distinct metabolic roles.  
i. Skeletal muscle glycogen 
 The insulin dependent transport of glucose into muscle is mediated by the 
GLUT4 transporter16,17. Upon entry into the cell, glucose is converted to glucose-
6-phosphate by the enzyme hexokinase II. In the resting state, glucose-6-
phosphate is targeted to either glycolysis for the generation of ATP or the 
biosynthesis of glycogen. Insulin dependent inhibition of glycogen synthase 
kinase 3 (GSK3) and dephosphorylation of GS by protein phosphatases promote 
the synthesis of glycogen12-14. Upon initiation of muscular contraction, breakdown 
of ATP increases cellular AMP levels, which in turn activates glycolysis by 
stimulating the enzyme phosphofructo kinase.  
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Figure 3. Regulation of glycogen metabolism in skeletal muscle.  
Schematic representation of the major signaling pathways regulating glycogen 
metabolism in the skeletal muscle. IR-Insulin receptor,βAR-βAdrenergic 
Receptor, GR- Glucagon receptor, PK – Protein Kinase, PI3K – Phosphotidyl 
inositol kinase, GSK3- Glycogen Synthase Kinase, PP1G- Protein Phosphatase, 
Gs- Glycogen Synthase, GPh – Glycogen Phosphorylase, AMPK- AMP 
dependent Protein Kinase, PhK – Phosphorylase Kinase 
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Release of calcium from the sarcoplasmic reticulum activates 
phosphorylase kinase, which phosphorylates and activates GPh thus simulating 
glycogenolysis. Glycogenolysis is also subjected to hormonal activation by 
epinephrine via protein kinase A (PKA) mediated activation of phosphorylase 
kinase. As muscular contraction continues, increases in the AMP levels activate 
AMP kinase, which stimulates glucose uptake. Further the muscle switches fuel 
utilization and oxidizes fatty acids to produce ATP. Repletion of the glycogen 
reserve is primarily through the insulin simulated uptake of glucose and GS 
activation in the fed state.   
ii. Liver glycogen 
 The major glucose transporter in the liver is GLUT2, which is expressed 
constitutively18. Hepatic glucose is phosphorylated by glucokinase (GK) the 
activity of which is regulated by the glucokinase regulatory protein (GKRP)19. 
GKRP binds to GK and retains it in the nucleus. Binding of glucose or fructose-
1P to GK releases GKRP and translocates GK to the cytoplasm. Insulin release 
promoted by the increased blood glucose levels, stimulates glycogenesis by 
inactivating glycogen synthase kinase3 (GSK3) and activating protein 
phosphatases. The decrease in blood glucose by fasting promotes glucagon 
release from the pancreas, which activates protein kinase A (PKA). PKA 
activates the phosphorylation cascade involving phosphorylase kinase and 
glycogen phosphorylase, thus stimulating the breakdown of glycogen.  
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4. Physiological role of glycogen in yeast 
In the budding yeast Sacccharomyces cerevisiae, glycogen accounts for 
20% of the dry weight of the cells and is one of the two major reserves of 
carbohydrate, the other being trehalose20,21. The amount of glycogen 
accumulated in the cell increases when the cell enters the stationary phase or 
upon depletion of essential nutrients like nitrogen and phosphorous in the growth 
media or by exposing the exponentially growing cells to high temperature, salt, 
oxidizing agents or ethanol22.  
 
Figure 4. Transcriptional and enzymatic regulation of glycogen metabolism 
in yeast.   
The phosphorylation state of Gsy2p and Gph1p are controlled by PKA and Snf1p 
in an antagonistic manner. Pho85p in association with Pcl10p phosphorylates 
and inactivates Gsy2p. The dephosphorylation is catalyzed by the phosphatase 
Glc7p in association with the targeting subunit Gac1p. The genes involved in 
glycogen metabolism contain STRE in the promoter and the transcription of the 
genes is activated by binding of Msn2/4p. PKA negatively controls the gene 
expression by inhibiting nuclear localization of Msn2p. 
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Yeast has two different isoforms of GS, of which the nutrionally regulated 
isoform-2 (GSY2) has shown to be the most important for the accumulation of 
glycogen in the cells23. Unlike the higher eukaryotes where the regulation of 
glycogen metabolism is primarily through the control of the enzyme activities, in 
yeast it involves both transcriptional and enzymatic responses. The 
transcriptional response is dependent on the presence of the cis-element – 
“stress response element (STRE)” in the promoter of the genes involved in 
glycogen pathways24. Under stress conditions, binding of the trans-activator 
Msn2p/Msn4p to the STRE causes a 2-3 fold transcriptional activation of these 
genes. The enzymatic control of glycogen deposition is through the glucose-6- 
phosphate mediated activation of GS and inactivation of GPh21 through 
phosphorylation. Exposure of the starved cells to nutrients activates GPh and 
inhibits GS resulting in the mobilization of glycogen. The response is biphasic25 
and involves a transient response via the glucose activated c-AMP dependent 
stimulation of PKA and a sustained response that involves a poorly characterized 
c-AMP independent fermentable growth medium pathway.  
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B. Glycogen synthase 
1. Glycogen storage disease type-0  
 GS is one of the rate limiting enzymes in the biosynthetic pathways of 
glycogen. Deficiency of the human liver glycogen synthase enzyme leads to 
GSD-0, which is inherited in an autosomal recessive manner. The deficiency 
causes a marked decrease in the liver glycogen content and is characterized by 
severe fasting hypoglycemia with associated symptoms including but not limited 
to lethargy, pallor, nausea and seizures in the morning before food intake. 
Fasting hypoglycemia is accompanied by hyperketonemia and low blood alanine 
and lactate levels. GSD-0 has been mapped to the GYS2 gene located at the 
chromosomal locus 12p12.2 and sixteen different mutations of GYS2 have been 
reported in GSD-026-28, which include two splice site variations, four premature 
stop codons, one deletion mutation and nine missense mutations (Figure 5). 
 Two recent studies have shown that mutations in the GYS1 gene could 
also lead to defects in glycogen storage29-31. The presence of a premature stop 
codon at position 462 of the human muscle GS causes abnormal heart rate and 
blood pressure after exercise and could lead to hypertropic cardiomyopathy29. 
Muscle biopsy from the patient shows severe lack of glycogen, extenstive 
mitochondrial proliferation and predominance of oxidative fibers29. Similar to the 
effects in humans, a R309H mutation in horse GYS1 leads to a polysaccharide 
storage myopathy30. The mutation has been reported to increase GS activity with 
12 
 
associated abnormal increase in glycogen accumulation in the skeletal muscles 
leading to muscle damage with exertion. 
  
 
  
Figure 5. GSD-0 mutation in human GYS2.  
Schematic representation of mutations reported in GSD-0 patients. The GYS2 
gene is represented as horizontal grey bar and the individual exons vertical black 
lines. The different types of mutations are color coded. 
 
 
2. Enzymatic activity of GS 
 In vitro, GS activity is determined by measuring the amount of 14C-glucose 
transferred from UDP-[14C] glucose to glycogen32. A unit of activity is defined as 
the amount of enzyme that catalyzes the transfer of 1 µmol of glucose from UDP-
glucose to glycogen per minute under the standard conditions of assay33 (4.4 mM 
UDP-glucose and 6.7 mg/ml glycogen). The activity ratio of GS enzyme is 
defined as the ratio of activity measured in the absence of glucose-6-phosphate 
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to that measured in the presence of 7.2 mM glucose-6-phosphate . The activity 
ratio serves as a kinetic index of the activation state of the enzyme34. 
3. Catalytic mechanism of GS 
 GS is a metal ion independent retaining Leloir type (nucleotide sugar 
donor) glycosyl transferase35,36. Three different mechanisms have been 
proposed and are being investigated for the retaining class of glycosyl 
transferases, as follows.  
i. SN2 Mechanism 
The SN2 mechanism was originally proposed by Koshland37, and involves 
two distinct nucleophilic displacement reactions and a covalent enzyme 
intermediate. It requires the presence of a catalytic nucleophile in the enzyme 
that initiates the reaction and a suitably positioned general acid/base that would 
assist the second nucleophilic attack (Figure 6). Enzymatic studies with human 
GYS1 led to the identification of the E-X7-E motif that is conserved across the 
eukaryotic GS enzymes38. Mutation of the first conserved glutamate to alanine 
resulted in an inactive human GYS1 whereas mutation of the second glutamate 
to alanine resulted in 90% reduction of activity. Based on these results, the 
authors proposed that these conserved glutamate residues function as the 
nucleophile and general acid/base catalyst in GS enzymes. 
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ii. SN1 Mechanism 
The SN1 mechanism for the retention of configuration at the anomeric 
carbon atom was first proposed by Philip for lysozyme39. The presence of an 
enzyme stabilized oxocarbenium ion intermediate could possibly shield and block 
the nucleophilic attack from the opposite face of the reaction center thus retaining 
the stereochemistry. However the free energy of the intermediate species and 
the associated transition states are very high. Since enzymes are believed to 
catalyze the reactions with lowest free energy intermediate species that would 
facilitate effective turnover, the SN1 mechanism for retaining glycosyl transferase 
enzymes is not widely accepted by biochemists. 
iii. SNi Mechanism 
The mechanism of decomposition of alkyl chlorosulfites was the basis for 
the development of the SNi (internal return) mechanism. The leaving group 
undergoes decomposition leading to the production of a nucleophile that is held 
as an ion pair. The retention of stereochemistry is attributed to the high rate of 
decomposition of the intermediate ion pair and the nucleophilic attack by the 
product. A modified version of the internal return mechanism has been proposed 
for glycogen phosphorylase40 and galactosyltransferase LgtC from Nisseria Sp41.  
The SNi mechanism for glycosyl transferases is partly based on the interaction 
between the departing phosphate of the sugar donor and the hydroxyl group of 
the acceptor42,43. 
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Figure 6. Proposed mechainsm of action for GS. 
The SN2 double displacement mechanism for retaining glycosyl transfer is 
depicted. The reaction involves two nucleophilic attacks, one by the catalytic 
nucleophile and the second by the activated 4’OH group of the acceptor. A 
suitably positioned general acid/base assists the second nucleophilic attack and 
the reaction involves a covalent intermediate. The SN1 mechanism on the other 
hand is mediated by the presence of a charge separated oxocarbenium ion 
intermediate that blocks the second nucleophilic attack from the opposite face of 
the reaction center.  
 
 
 
 
 
 
 
 
 
 
 
B: 
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4. Influence of substrate on GS activity 
Early studies of rabbit GYS1 with sugar acceptors of varying polymer 
length demonstrated that the S0.5 of the sugar acceptor and the Vmax of the 
enzyme changed significantly as the acceptor length was increased from three 
(maltotriose) to four (maltotetraose)44. When maltotetraose, maltohexaose and 
hydrolyzed amylose were used as acceptors there was no significant change in 
the enzymatic properties. However, when amylopectin subjected to varying levels 
of digestion by β-amylase was used as the substrate, a decrease in the Vmax was 
observed as the chain length was decreased. When comparing maltose and β-
amylase limit dextrin (two sugars in the outer chain) substrates, the Vmax of the 
enzyme differed by four-fold, but the S0.5  changed by five orders of magnitude. 
Based on these observations, the authors proposed the presence of distinct 
polysaccharide binding and catalytic sites in GS (Figure 7). Longer sugar 
polymers that occupy both the sites serve as better substrates for the enzyme. 
Further, Larner et al. hypothesized that the catalytic site is composed of a 
minimum of four identical sub-sites, the greater occupancy of which leads to 
greater enzymatic efficiency44.  
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Figure 7. Model of active site and polysaccharide binding site of GS. 
Presence of separate catalysis and polysaccharide binding site in rabbit muscle 
GS. Sugar polymers that bind simultaneously to both the sites are better 
substrates for the enzyme. The active site is composed of four identical sub sites 
and acceptors that occupy a greater number of these sites act as better 
substrates. 
 
5. Regulation of GS activity 
 The activity of eukaryotic enzymes is regulated by multiple mechanisms 
including covalent modification, allosteric activators and translocation within the 
cells. There are common regulatory themes – phosphorylation control and 
allosteric activation by glucose-6-phosphate, but the physiological responses that 
impinge on these regulatory controls often differ amongst different organisms and 
even between tissues of the same organism. 
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i. Regulation by covalent modification 
 
Figure 8. Schematic of human GYS1.  
Schematic representation of human muscle GS. The phosphorylation sites and 
arginine cluster are represented as black and grey boxes the actual sequences 
are shown below. The phosphorylation sites and the conserved arginines are 
highlighted in red and blue respectively. 
 
 
 
 Hierarchal ATP-dependent phosphorylation by protein kinases of serine 
and threonine residues within conserved regions located at both the N- and C-
terminal ends of the mammalian GS enzymes inhibits enzyme activity45,46. 
Phosphorylation of the rabbit GYS1 increases the S0.5 value of the UDP-glucose 
substrate from 0.75 mM to 61 mM47. Mammalian GS enzymes have two potential 
phosphorylation sites in the N-terminal 20 amino acids and five to seven 
phosphorylation sites in the C-terminal 80-100 amino acids. Phosphorylation of 
the sites 3a-c has maximal effect on the enzymatic activity and studies with COS-
M9 cells expressing the wild type and site 3a-c mutants have demonstrated that 
loss of these sites strongly correlates with increased glycogen accumulation48,49. 
Dephosphorylation of GS by type1 protein phosphatases (PP1) reverses the 
phosphorylation state of GS and a number of targeting subunits like RGL50. GL51, 
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PTG52 and PPP1R653 are involved in targeting PP1 to GS and glycogen. The 
importance of these targeting subunits for proper recruitment of PP1 is 
demonstrated by studies with knock-out mouse models. The skeletal muscle 
tissue of RGL knock-out mice exhibit hyper phosphorylated GS which correlates 
well with the reduced glycogen levels in the muscle54. Decreased hepatic 
glycogen synthesis in insulin dependent diabetic rats has been linked to the 
decreased level of GL espression in the liver of these animals55. 
 Both N and C terminal phosphorylation sites of mammalian GS are 
involved in mediating insulin sensitivity56 and impaired insulin regulation of GS in 
obesity and type 2 diabetes mellitus have been linked to the dysregulation of 
phosphorylation at sites 2, 2a and 3a-c of human muscle GS57. It has been 
reported that O-linked N-acetylglucosamine modification of GS restrains the 
enzyme in a glucose-6-phosphate dependent state and decreases the activation 
of the enzyme by insulin58.  
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Figure 9. Schematic of Gsy2p. 
The phosphorylation sites and arginine cluster are represented as black and grey 
boxes and the actual sequences are shown below. The phosphorylation sites 
and the conserved arginines are highlighted in red and blue respectively. 
  
Yeast Gsy2p lacks the hierarchal phosphorylation control mechanisms 
and the N-terminal regulatory phosphorylation sites of the mammalian forms of 
GS but retains the inhibitory effects of C-terminal phosphorylation. In yeast, the 
C-terminal regulatory phosphorylation sites are residues Ser 651, Ser 655 and 
Thr 66859. Gsy2p truncated at residue 644 had a higher activity ratio and 
synthesized 4-fold more glycogen than its wild type counterpart59. Mutation of the 
Thr668 phosphorylation site to alanine resulted in a 35% increase in the activity 
ratio and an associated increase in glycogen accumulation59. In yeast, it has 
been established that phosphorylation of the GSy2p is mediated by the cyclin 
dependent protein kinase Pho85p60 in association with the cyclin-like Pcl10p61  
subunit that activates and targets the kinase complex to the substrate. Studies 
with aspartate mutants of the phosphorylation sites in Gsy2p showed that the Thr 
668 site was the most important site for activity control as only the mutant at this 
position showed decrease in activity62. However, the activity ratio of the T668D 
mutant did not show any considerable change suggesting that the aspartate 
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mutants are not actual phosphomimics for Gsy2p. Further evidence for the 
influence of Thr 668 on enzyme activity is the drastic decrease in the activity 
observed when the S651A/S655A double mutant was phosphorylated by the 
Pho85p/Pcl10p or Pcl8p complex (Roach and Wilson, unpublished). Similar to 
the mammalian enzymes dephosphorylation of Gsy2p involves a complex 
between the type-1 protein phosphatase Gac1p and its targeting subunit 
Glc7p63,64. Loss of GAC1 function leaves Gsy2p in the inactive from and 
decreases glycogen accumulation in the cells.  
ii. Allosteric regulation 
 Inhibition of GS by phosphorylation can be overcome by the allosteric 
activator glucose-6-phosphate, which increases the Vmax of Gsy2p by 2.5 fold62. 
In contrast, the effect of glucose-6-phosphate on the mammalian enzymes is 
primarily on substrate binding kinetics. It decreases the S0.5 for UDP-glucose 
from >30 mM to ~50 µM with little effect on the Vmax47,65. Alanine scanning 
mutagenesis of a conserved arginine rich sequence near the C-terminal portion 
of Gsy2p led to the discovery of its role in conferring sensitivity to glucose-6- 
phosphate and phosphorylation62. Triple mutation of the first three arginine 
residues to alanine (R580A/R581A/R583A) abrogated activation by glucose-6- 
phosphate and inhibition by phosphorylation. Mutation of the second set of three 
arginines also disrupted glucose-6-phosphate activation, but the enzyme could 
still be inhibited by phosphorylation. The same set of alanine mutations in the 
rabbit GYS1 enzyme also resulted in the loss of glucose-6-phosphate activation. 
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However, their sensitivity to inhibition by phosphorylation was swapped such that 
mutation of the N-terminal set of arginines retained inhibition by 
phosphorylation66.  
iii. Regulation by cellular translocation 
 Enzymes involved in glycogen synthesis change their intracellular 
localization in response to cellular glucose levels and this provides an additional 
mechanism of regulation. Insulin and glucose dependent redistribution of GS has 
been reported in skeletal muscle67, adipocytes68 and hepatocytes69. One study 
with GFP fused muscle GS expressed in C2L2 and COS-1 cells showed that the 
chimeric GS is localized near the nucleus at low glucose concentrations and 
upon increasing the concentration of glucose, it translocates to the cytosol and 
later adopts a punctate pattern of distribution67. A recent study with rabbit skeletal 
muscle has demonstrated that phosphorylation at sites 1b, 2 and 2a could 
regulate this redistribution70. Liver GS, on the other hand, is cytosolic even in the 
absence of glucose. However as the glucose levels are increased, an initial 
accumulation of GS at the periphery and subsequent distribution into the cytosol 
has been observed69. The redistribution of GS correlates well with the hepatic 
glycogen accumulation, which is initiated at the periphery and moves towards the 
interior as the glycogen deposits grow14.  
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iv. Three state model for the regulation of yeast Gsy2p 
 Based on kinetic and mutational studies, a three state model has been 
proposed for the control of Gsy2p activity62. In the dephosphorylated state (I 
State), the enzyme exists in a intermediate activity state that has high sensitivity 
to glucose-6-phosphate (R State). Binding of glucose-6-phosphate converts this 
to the highest activity state. Phosphorylation of the intermediate form reduces the 
activity by 30 fold and decreases the sensitivity to glucose-6-phosphate by about 
20 fold to generate the lowest activity state (T State). When exposed to 
saturating concentrations of glucose-6-phosphate, the phosphorylated form binds 
to glucose-6-phosphate and exhibits highest activity. 
 
 
Figure 10. Three state model for the regulation of Gsy2p activity. 
 A three state model has been proposed for Gsy2p based on the kinetic and 
mutational studies. The dephosphorylated enzyme exhibits intermediate activity 
which upon binding to glucose-6-phosphate shows highest activity. 
Phosphorylation of the intermediate state decreases the activity by 30 fold. 
Figure adapted from J Biol Chem. 275, 27753-61, (2000). 
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6. Structural classification of GS  
 Sequence analysis, as well as more recent structure determinations, have 
grouped the GS enzymes within the GTB-fold of glycosyl transferases71. These 
structures are characterized by the presence of two Rossmann fold domains with 
a deep interdomain cleft in between that harbors the substrate-binding and 
catalytic sites. Within the larger group of GTB-fold enzymes, the GS enzymes are 
further subdivided into two families, GT3 and GT5. The bacterial and archaeal 
GS enzymes are grouped into the GT5 family and are not subjected to any 
known allosteric or covalent regulation. The eukaryotic enzymes are grouped into 
the GT3 family and are regulated through the allosteric activator glucose-6-
phosphate and inhibitory phosphorylation. An additional point of distinction is that 
the bacterial enzymes use ADP-glucose as their sugar donor, whereas 
eukaryotic enzymes almost exclusively utilize UDP-glucose as their donor 
molecule. Archaeal enzymes are capable of using both ADP and UDP-glucose 
as sugar donors. To date, three dimensional structures have been determined for 
three members from the GT5 family - a monomeric E.coli enzyme72,73, dimeric 
Agrobacterium tumefacians enzyme74 and trimeric Pyrococcus abyssi enzyme75. 
However these structures have shed little light on the regulatory mechanisms 
controlling eukaryotic enzymes. 
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Figure 11. Schematic representation of the carbohydrate active enzymes 
(CAZy) classification of GS.  
GS enzymes are grouped in the GTB fold and are further divided into two 
subgroups based on their regulatory properties. The structures of the three 
available GT5 enzymes are shown in ribbon representation and the individual 
monomers are highlighted in green.   
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C. Rationale and overview of the thesis research 
The overall goal of this project is to understand the molecular mechanism 
of regulation of GT3 class of glycosyl transferase enzymes. We are studying the 
yeast Gsy2p as a model enzyme as it retains the regulatory mechanisms of the 
mammalian enzymes and shares 50% sequence identity to the mammalian 
enzymes.   
The specific aims of this work include 
a. Solving the three dimensional structure of Gsy2p in different activity states 
b. Investigating the structural and functional consequence of the C-terminal 
phosphorylation of Gsy2p 
Three major approaches have been implemented in the studies that include  
a. Macromolecular X-ray crystallographic studies of the enzyme and enzyme 
complexes with activators and substrate analogs 
b. Site-directed mutageneis and kinetic analysis of the mutants 
c. Intein mediated peptide ligation approach to generate homogeneously 
phosphorylated forms of Gsy2p for kinetic and enzymatic studies 
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D. Theory of experimental methods used 
1. Macromolecular x-ray crystallography 
 The purpose of this session is to provide a brief overview of the principles 
of X-ray crystallography and focus on (a) the multiple isomorphous replacement 
method of solving the phase problem and (b) the Patterson method76 for solving 
the position of heavy atoms introduced into isomorphous derivatives.  
i. Overview of the principles of macromolecular crystallography  
 Macromolecular structure determination by X-ray crystallography is based 
on the principle of diffraction of X-rays by the electrons associated with the 
protein molecules present in a crystal. Crystals consist of an ordered 
arrangement of protein molecules in a repeated arrangement within a unit cell, 
which is translated in three dimensions to form the lattice. Each unique crystal 
belongs to a particular space group, which specifies the symmetry relationship 
within the unit cell and is characterized by unique cell dimensions. Indexing the 
diffraction data refers to the process of determining these unit cell parameters 
and mathematically identifying each reflection by integral indices h, k and l. Each 
diffraction spot could be considered as reflection of the X-rays from an imaginary 
set of equidistant parallel planes identified by the indices h, k and l for the 
intercepts 1/h, 1/k and 1/l that the planes intersect with the unit cell edges a, b 
and c (Figure 12). 
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 The reflections from the imaginary set of planes obey Bragg’s law  
    2d sin θ = n λ 
where d is the distance between the planes, θ is the angle between the plane 
and the incident rays, n is an integral whole number and λ is the wavelength of X-
rays. 
 
Figure 12. Bragg’s law. 
A two-dimensional crystal lattice and a set of imaginary planes is represented by 
the grid. X-rays incident on the crystal at an angle θ produce coherent diffraction 
(in phase) when the difference in the distance travelled (2d sinθ) is equal to an 
intergral number of the wavelength (nλ). Figure adapted from 
http://reference.iucr.org/dictionary.                        
 
The scattering of x-rays from the unit cells is dependent on the 
arrangement of the atoms in the unit cells. Each atom in the unit cell contributes 
to the diffraction by a structure factor that is characterized by a magnitude and 
phase angle, which depend on the atom type and scattering angle.   
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The structure factors can be described in the complex co-ordinate form as  
   A+iB = F (cos Φ+I sin Φ) 
or is represented as a vector in the complex plane shown in Figure 13.  
  
Figure 13. Vector representation of the structure factor.  
The structure factor is represented as a vector A+iB / F (cos Φ+I sin Φ) in the 
complex plane. The amplitude or modulus of the structure facture is given by 
(A2+B2)1/2 and the phase angle Φ = tan-1 (B/A). (Figure adapted from X-ray 
structure determination – A practical guide. Stout and Jensen. Pg. 198) 
  
  
The X-ray scattering from all the atoms of the unit cell are added to obtain 
the overall structure factor Fobs (h,k,l ), which is a vector describing the reflections 
from all the planes of index h,k and l. The overall structure factor is described as 
the summation of all the individual structure factors as   
  Fobs (h,k,l ) = Σ f 0 ( i )  ∙ ( cos φ hkl + i sin φ hkl ) 
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The magnitude of this structure factor is related to the intensity of the 
diffracted x-rays  
   I obs (h,k,l ) ∝ | Fobs (h,k,l ) | 2 
The electron density of the molecules ρ (x,y,z) in the unit cell is calculated in the 
real space coordinates (x,y,z) using a Fourier synthesis of the structure factor 
amplitudes Fobs (h,k,l ), phase φ (h,k,l) and the unit cell volume (V) by the relation   
     ρ (x,y,z) = V-1  ∙ Σ h,k,l  | Fobs (h,k,l ) | cos 2π [ (hx+ky+lz) – φ (h,k,l) ] 
 Thus, to compute the electron density, we need both the amplitude and 
the phase information of the scattered X-rays. The intensity of the diffracted data 
(i.e. the square root of amplitude) is recorded when collecting data, but the phase 
information is completely lost. Hence it is impossible to determine the structure 
with the diffraction data alone. Several methods including multiple isomorphous 
replacement have been developed to solve the phase problem in crystallography. 
ii. Phasing by multiple isomorphous replacement 
 Multiple isomorphous replacement, the most common method for 
experimental initio phasing was introduced by David Harker77, but was first 
successfully applied in proteins to solve the structure of hemoglobin by Max 
Perutz78. The method involves the use of heavy atoms that are sufficiently 
electron dense as marker atoms to provide phase information. The heavy atom 
derivatives are prepared by soaking the native protein crystals with the heavy 
atom solution or by cocrystallizing the protein with the heavy atom. The presence 
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of additional electrons in the heavy atom will significantly change the scattered 
intensity of the X-rays. By comparing the native and the derivative data, we can 
compute the position of the heavy atom in the crystal and thus its contribution to 
the structure factor and the phase angle. 
The structure factor of a isomorphous derivative (FPH) is related to the sum 
of the structure factor of the protein (FP) and that of the heavy atom (FH)   
and is represented by a phase triangle.  
   
    
Figure 14. Phase triangle.  
A vector diagram illustrating the contributions of the native protein (FP) and the 
heavy atom (FH) to the structure factor of the heavy atom derivative (FPH). (Figure 
adapted from Protein Crystallography. Blundell and Johnson. Pg. 156) 
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The method of isomorphous replacement phasing is represented in the 
vector format by the Harker construction76 (Figure 15). A circle (blue) with radius 
equal to the amplitude of protein |FP | centered at the origin (O) represents all the 
vectors that would be obtained with all the possible phase angles for FP. If we 
now generate a new circle (green) with radius |FPH1| centered at a point defined 
by -|FH| from the origin, this would represent all the possible values for FP that 
satisfy the equation FPH1 = FH1 + FP while agreeing with the measured amplitude 
|FPH1|. The two points of intersection of these circles (H, L) represent the two 
possible values for the phase angles (FP) that agree with both the measured 
amplitudes and with the heavy atom model. Thus, each derivative would give two 
possible phase values; one correct and one incorrect. This phase ambiguity is 
overcome by preparing a second different heavy atom derivative or using the 
anomolous scattering signal. The information from the second heavy atom 
derivative (red circle) in combination with the first will give the only phase choice 
that is consistent with all the information. 
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Figure 15. Harker construction for phase determination by the method of 
multiple isomorphous replacement. 
 Circles of radii FP (blue), FPH1 (green) and FPH2 (red) are drawn with their centers 
at O, J and K respectively and the corresponding widths represent their individual 
errors in measurement. The vectors OJ and OK represent –FH1 and –FH2 the 
heavy atom contributions to the structure factor of the derivatives. The vector OH 
that defines the point of intersection of the three circles represents the magnitude 
and phase information of FP. The error in phase estimation (lack of closure) is 
represented by the white bar and depicts the variation in possible phase 
assignment due to measurement or non-isomorphism error. (Figure adapted from 
Protein Crystallography. Blundell and Johnson. Pg. 161) 
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A perfect isomorphous derivative is one in which the crystal lattice is 
unperturbed by the addition of the heavy atom. In practice there is always some 
non-isomorphism between the native and derivative and this in combination with 
the errors is the measurement of the structure factor amplitudes results in the 
lack of closure of the phase triangle. The phase probability in the multiple 
isomorphous replacement method is the product of the individual normalized 
probabilities of each derivatives and is represented as  
   P(φ ) = N Π j exp ( -εj2 (φ ) / 2Ej2 ) 
where N is the normalization factor, ε ( φ ) is the lack of closure of the triangle 
and E is the standard deviation. Thus MIR should yield one common solution 
with maximum probability among all the derivatives that represents the most 
probable phase and is calculated at the centroid of the probability distribution as 
   Fbest = m |Fp| exp (i φbest) 
where m is the figure of merit and is the probability of φbest being correct. If the 
error in phase angle at a given φi is defined as Δφi = φbest - φi , m is the mean 
value of the cosine of error in the phase angle 
   m = cos Δφi  
A value of m = 1 corresponds to zero error in the phase angle measurement, 
while m = 0.5 corresponds to a phase error of 60°. 
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iii. Patterson function 
 The Patterson function was introduced by Arthur Lindo Patterson and is a 
modification of the electron density function where the structure factors originally 
represented by their amplitudes and phases are replaced by the square of their 
amplitudes that are proportional to the intensity of the diffracted X-rays. 
  P(u.v.w) = V-1 ∙ Σ h,k,l  | Fobs (h,k,l ) | 2 cos 2π (hu+kv+lw)  
where P(u.v.w) is the Patterson function and Fobs (h,k,l ) is the amplitude of the 
structure factor. The Patterson function is essentially a Fourier transform of the 
intensities rather than the structure factors. The Patterson function generates a 
centro-symmetric map of the inter-atomic vectors between atoms in the crystal 
structure. A peak at a position u,v,w in the Patterson map indicates that atoms 
exist in real space at positions x1,y1,z1 and x2,y2,z2 such that u = x1-x2, v =y1-
y2, w = z1-z2. For a crystal with N atoms in the unit cell, the Patterson map will 
show N2 peaks of which N will be the self vectors. The height of the peaks in the 
Patterson map is proportional to the product of the atomic numbers of the atoms 
involved and thus the Patterson map can be used for locating the heavy atoms in 
the molecule since the function is dominated by the square of the largest terms. 
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Figure 16. Patterson Function.  
Representation of the Patterson function of a crystal with three atoms. The 
Patterson function is a map of all inter-atomic vectors between the atoms in the 
cell. (Figure adapted from Protein Crystallography. Blundell and Johnson. Pg. 
138) 
 
 Harker showed that the interatomic vectors between equivalent atoms of 
the unit cell that are related by the symmetry operations produce peaks (Harker 
peaks) that are concentrated at certain planes or along certain lines determined 
by the known crystallographic symmetries of the unit cell76. These portions of the 
Patterson map are termed “Harker sections” and they provide an easy method 
for solving the atomic positions of electron dense atoms in the crystals through 
visual inspection of these sections. 
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iv. Solving the heavy atom position using the Patterson function  
 The primitive monoclinic P21 space group has one two-fold screw axis 
parallel to the b axis. The symmetry related general equivalent positions in the 
P21 space group are x, y, z and -x, ½+y, -z. The self-vectors in the Patterson for 
the P21 space group are calculated by subtracting one equivalent position from 
the other and are given by u, v, w = 2x, ½ , 2z. The Harker vector always occurs 
in the section defined by v = 1/2, which is generated by the 2-fold screw axis 
along b.  
Thus for the P21 space group, 
  (2x, ½ , 2z ) = (u, v, w )    or  (-u,- v,- w ) 
       or (u+1, v, w )    or  (-u+1,- v,- w ) 
    or (u, v, w +1)    or  (-u,- v,- w+1) 
    or (u+1, v, w +1)   or  (-u+1,- v,- w+1) 
Using these relations, the equivalent positions of x and z in the real space co-
ordinates can be calculated from the Patterson co-ordinates, but the y positions 
are unspecified. However since there is no unique origin point along the b axis in 
the P21 space group, the y value can be assigned arbitrarily. When two or more 
sites are present, the relative y value can be assigned using the cross-vectors 
between the sites79. The cross vectors are calculated by subtracting the positions 
of the individual sites and every pair of unique sites will have its own cross 
vector. 
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2. Intein mediated peptide ligation 
 Inteins are self-splicing protein elements and the process by which 
splicing occurs consists of four nucleophilic displacement reactions directed by 
residues in the inteins and the adjacent exteins80. The first step involves the 
N→S or N→O acyl shift and the N-extein is transferred to the first residue of the 
intein (Figure 17). This rearrangement is followed by a trans-esterification step 
and the N-extein is transferred to the side chain of a conserved cysteine or serine 
residue located at the intein C-extein junction. Succinimide formation involving a 
conserved asparagine residue within the intein breaks the amide bond between 
the intein and the extein and releases the intein. The final step in splicing 
involves a S→N acyl shift that facilitates the formation of a peptide bond between 
the N-extein and C-extein. 
 The process of protein splicing has been used in the expressed protein 
ligation or intein mediated peptide ligation approach that facilitates the ligation of 
synthetic peptides to recombinant proteins80,81. The recombinant protein is 
expressed in fusion with a chitin binding domain from Bacillus circulans and this 
enables the affinity purification of the fused protein with chitin beads. Similar to 
the protein splicing the first step in expressed protein ligation involves a N→S 
acyl shift of the recombinant protein to the cysteine residue of the intein. 
However the conserved asparagine is mutated to alanine and this prevents the 
release of the intein. Addition of a thiol reagent with a synthetic peptide that has 
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cysteine residue in the first position favors a trans thioesterification and S→N 
acyl shift, thus generating a semisyntheic protein.  
 
 
Figure 17. Mechanism of intein splicing.  
Schematic representation of the nucleophilic reactions involved in the protein 
splicing and the expressed protein ligation method. Figure adapted from 
Structure. 6: 951-956 (1998) 
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METHODS 
A. Gsy2p wild-type and mutant expression constructs 
1. Site-directed mutagenesis 
 The wild-type, R580A/R581A/R583A and R587A/R589A/R592A Gsy2p 
His tagged construct in the pET28A E.coli expression plasmids were obtained 
from Roach lab. The other mutant constructs were created from these constructs 
using the PCR based site-directed mutagenesis approach82. Primers for 
amplification for site directed mutagenesis were designed and ordered from 
Integrated DNA Technologies. The PCR amplification of the plasmids was 
performed using the Pfu Turbo polymerase from Stratagene. The parental 
plasmid in the amplified reaction mix was digested with Dpn I (New England 
Biolabs) and the Dpn I treated sample was introduced into competent E.coli DH5-
α cells. Isolated transformed colonies were inoculated in LB broth containing 
kanamycin (50 µg / mL) and grown to OD600 of 0.7. The Promega WizardPlus SV 
miniprep kits were used for the purification of plasmid DNA from the transformed 
colonies. The mutations were confirmed by DNA sequencing of the plasmids at 
the DNA Sequencing Core Facility of IU School of Medicine.  
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2. Cloning of Gsy2p in the IMPACT vector 
 The yeast Gsy2p cDNA fragment encoding amino acids 1-640 was 
amplified from the original pET28A expression construct. The oligonucleotides for 
amplification were obtained from Integrated DNA technologies. The amplified 
cDNA was sub-cloned into the Nde I and Sap I sites of the IMPACT vectors 
pTXB1 and pTYB1 (New England Biolabs) and the ligated vectors were used to 
transform competent E.coli DH5-α cells. The transformed colonies were tested by 
the colony PCR method to check the insert size in the plasmid DNA. The 
colonies that showed the presence of the 2kb insert were inoculated in LB 
containing ampicillin (100 µg / mL) and were grown at 37°C to OD600 of 0.7.  
Plasmid DNA isolation from the cultures was performed using the Promega 
WizardPlus SV miniprep kits. In-frame ligation of the Gsy2p cDNA to the 
plasmids was confirmed by DNA sequencing at the DNA Sequencing Core 
Facility of IU School of Medicine using the T7 forward and MXe-intein reverse 
primers. 
B. Peptide synthesis 
 Two 35-mer peptides corresponding to the C-terminal phosphorylation site 
of the Gsy2p were synthesized by the Peptide Synthesis Core of the 
Biochemistry and Biotechnology facility of Indiana University, School of Medicine. 
Subsequently two 49-mer peptides with additional 14 residues towards the C-
terminal region were synthesized from Antagene.  
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The peptide sequences were as follows:  
35mer Non-phosphopeptide  
CKLKVARPLSVPGSPRDLRSNSTVYMTPGDLGTLQ 
35mer Phosphopeptide  
CKLKVARPLSVPGSPRDLRSNSTVYMT(PO3)PGDLGTLQ 
49mer Non-phosphopeptide 
CKLKVARPLSVPGSPRDLRSNSTVYMTPGDLGTLQEVNNADDYFSLGVN 
49mer Phosphopeptide  
CKLKVARPLSVPGSPRDLRSNSTVYMT(PO3)PGDLGTLQEVNNADDYFSLGVN 
C. Expression and purification of Yeast Gsy2p 
1. Protein preparation from pET28A constructs 
 The full-length yeast Gsy2p was expressed with the N-terminal His-tag 
(pET28A) in E.coli BL21 cells. Cultures were grown at 37°C to OD600 of 0.6 and 
induced with 0.1 mM IPTG at 16°C for 16 hours. Cells were collected by 
centrifugation and resuspended in lysis buffer containing 20 mM Tris pH 8.0, 300 
mM NaCl, 10 mM imidazole, 2 mM Benzamidine, 1 mM β-mercapto ethanol 
(BME) and 0.1% TritonX-100. Cells were lysed by passage through French 
pressure at 17,000 psi and the lysate was clarified by ultracentrigugation at 
35,000 rpm for 35 min. The clarified lysate was loaded on a Ni2+-nitrilotriacetic 
acid-agarose (Qiagen) column pre-equilibrated with the lysis buffer. The column 
was washed to base line with the lysis buffer. Buffers with 25 mM and 50 mM 
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imidazole were used for additional wash steps to elute the non- specifically 
bound proteins. The bound Gsy2p was eluted with a linear gradient of 50 to 200 
mM imidazole in the lysis buffer. The collected fractions were analyzed by 
running on a 10% SDS-PAGE gel and those containing Gsy2p were pooled and 
dialyzed against the Q-load buffer containing 50 mM Tris pH 8.0, 1 mM EDTA, 2 
mM benzamidine and 1 mM BME. The dialyzed sample was loaded on to Q-
sepharose fast flow (GE Healthcare) column pre-equilibrated with the Q-load 
buffer. The column was washed to base line with the Q-load buffer and bound 
protein was eluted with a linear gradient of 0-1M NaCl in the Q-load buffer. The 
collected fractions were analyzed by SDS-PAGE and fractions that contained 
>90% Gsy2p (visualized by Coomassie staining) were pooled and dialyzed 
against 20 mM Tris pH8.0 and 1 mM BME. The dialyzed protein was 
concentrated to 4-5 mg/ml at 4°C using either Amicon Centricon-30 or Pall 
Macrocon -50 centrifugal concentration devices. The concentrated protein was 
filtered through microfuge centrifugal filters, aliquoted to small volumes, flash 
frozen in liquid nitrogen and stored at -80°C. 
2. Purification of Gsy2p core and semi-synthetic enzymes  
 The expression of the intein -chitin binding domain (CBD) fused Gsy2p 
from both the PTXB1 and PTYB1 were tested. Overnight induction at 16°C with 
0.3 mM IPTG showed comparable levels of expression of the fusion protein from 
both the plasmids as analyzed by western blot using the anti-CBD antibody. 
Various thiol reagents including DTT, BME, MESNA and thiophenol at three 
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different temperatures - 4°C, 16°C and Room temperature (25°C) were tested for 
cleavage activity. The pTXB1 construct was chosen for the Gsy2p preparation as 
the protein purification from this construct resulted in reasonable protein yield (~5 
mg from 2 L) in a reproducible manner. The detailed protocol for the expression 
and purification of Gsy2p from the PTXB1 consturct is given below.   
 E.coli ER2566 cells transformed with the pTXB1- yeast Gsy2p plasmids 
were grown in LB medium containing 100μg/mL ampicillin at 37°C to 0.6 OD600 
and induced with 0.3 mM IPTG at 16°C for 16 hr. Cells were harvested and 
resuspended in lysis buffer (20 mM Tris pH 8.5, 500 mM NaCl, 2 mM EDTA, 2 
mM Benzamidine, 1 mM PMSF and 0.1% Triton X-100). Cells were lysed by 
passage through the French press at 17,000 psi and the lysate was clarified by 
ultracentrifugation at 35,000 rpm for 35 min. The clarified lysate was loaded on to 
chitin resin (New England Biolabs) pre-equilibrated with buffer containing 20mM 
Tris-HCl and 500mM NaCl pH 8.5. The column was washed to base line with 
equilibration buffer (20 mM Tris pH 8.5, 500 mM NaCl, 2 mM EDTA, 2 mM 
benzamidine and 1 mM PMSF).  
 For the 1-640 truncated core enzyme, the column was treated with 
equilibration buffer containing 50 mM DTT and after standing at 25°C for 20hrs, 
the cleaved protein was eluted with the equilibration buffer. The semi-synthetic 
peptide ligated proteins were generated by treating the column with 2 ml of 2% 
v/v thiophenol in equilibration buffer followed immediately by 1 ml of 1 mM 
synthetic peptide and 2% thiophenol in equilibration buffer. After standing at 25°C 
for 20 hrs, the cleaved peptide ligated semi-synthetic protein was eluted with the 
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equilibration buffer. We observed that some amount of the cleaved Gsy2p was 
still bound to the chitin beads and hence an additional elution step with 50 mM 
maltose in the elution buffer was included. The eluted protein was subjected to 
dialysis against 20 mM Tris pH 8.0, 1 mM DTT and decreasing NaCl 
concentrations starting from 500mM to 0 mM, to remove the unligated peptide, 
salt and excess reducing agent. For the truncated protein all the dialysis were 
performed at 4°C. When the semi-synthetic proteins were generated, the first 
dialysis step was performed at 25°C to avoid precipitation of the thiophenol in the 
cold aqueous buffers. The purified enzymes were analyzed on a 10% SDS-
PAGE gel and further concentrated using with Amicon Centricon-30 centrifugal 
concentration devices to a final concentration of 3 mg/mL. Ligation of the peptide 
was confirmed by running the protein with the His-tagged full length and 640 
truncated control proteins on a 7% SDS-PAGE gel. The concentrated protein 
was aliquoted to small volumes, flash frozen in liquid nitrogen and stored at -
80°C.  
D. Crystallization of Gsy2p 
1. R580A/R581A/R583A crystals 
 Crystals of Gsy2p – R580A/R581A/R583A mutant were grown in hanging 
drops by combining 2µl protein at 3mg/ml with 2µl reservoir solution containing 
100 mM Tris-HCl pH 8.0-8.5, 200 mM Li2SO4 and 18-22% PEG 3400. Physically 
twinned six-sided plate clusters of crystals were obtained in 3-5 days. These 
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crystals were used for making seed stock solutions using the seed bead kit from 
Hampton Research. The seed stock solutions were prepared in the crystal 
stabilizing solution containing 100 mM Tris - HCl pH 8.3, 200 mM Li2SO4 and 
25% PEG 3400 and serial dilutions of the seed stocks were made with the same 
stabilizing solution. Both the streak seeding and microseeding techniques were 
used and the microseeding gave reproducible results. Trapezoidal crystals of 
Gsy2p appear in 5 days and grow to a length of 200 µm in two weeks. 
 Glycerol to a final concentration of 20% was used as the cryoprotectant for 
freezing the crystals. The crystals were incubated in the mother liquor with 6% 
glycerol for 16 – 20 hours before harvesting. The treated crystals were 
transferred quickly to the mother liquor with 10% and 20% glycerol and were 
flash frozen at -180°C in the gaseous nitrogen stream on the X-ray machine.  
2. R589A/R592A glucose-6-phosphate Co-crystals 
Screening for crystallization conditions of the GSy2p – R589A/R592A 
mutant, with and without glucose-6-phosphate (25 mM) was performed using the 
commercially available crystal screens from Hampton Research and Emerald 
Biosystems. The hanging drop vapor diffusion method was used for the 
screening and the drops were set by combining 2 µl protein at 3 mg/mL with 2 µl 
of the crystallization solution. Crystal plates were incubated for 1 week at room 
temperature. One condition (100 mM Bis-Tris pH 6.5, 25% PEG 300) with which 
the R589A/R592A double mutant crystallizes only in the presence of glucose-6- 
phosphate was discovered and was chosen for further optimization. 
47 
 
Co-crystals of the yeast Gsy2p – R589A/R592A mutant with glucose-6- 
phosphate were grown in hanging drops by combining 2 µl protein at 3 mg/mL 
and 50 mM glucose-6-phosphate with 2 µl reservoir solution containing 100 mM 
Bis-Tris pH 6.2-6.5, and 18-22% PEG 300. Cryoprotection worked best if the 
crystals were first dehydrated by replacing the mother liquor with a solution 
containing the same buffer containing 30% PEG 300 and re-incubating the plates 
for 48-60 hours before harvesting. The stabilized crystals were quickly coated 
with immersion oil before freezing at -180°C in the gaseous nitrogen stream. 
3. Heavy atom and ligand soaks 
 The trapezoidal R580A/R581A/R583A crystals were transferred to the 
crystallization solution with the same buffer and 200 mM Li2SO4 but 30% PEG 
3400 (stabilizing solution) and incubated for 12 hours. Heavy atom derivatives of 
the stabilized R580A/R581A/R583A crystals were prepared by soaking the 
crystals in the crystal stabilizing solution containing 1 mM Ta6Br12 83 for 6-12 
hours. The UDP and maltooctaose complexes with Gsy2p were prepared by 
soaking the native crystals in the crystal stabilizing solution containing 20 and 50 
mM of the respective compounds. All the ligand and heavy metal soaked crystals 
were cryoprotected and frozen in the same way as the native 
R580A/R581A/R583A crystals. 
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E. Data collection, processing, structure solution and refinement 
1. Data collection 
i. R580A/R581A/R583A data sets 
 The 2.9 Å native data set and the tantalum derivative data sets were 
collected at the 19-ID beamline operated by the Structural Biology Center at the 
Advanced Photon Source located at the Argonne National Laboratory. 
Fluorescence scans were performed on the tantalum derivatives and data 
collection was initiated at the peak wavelength for these derivatives; 1.25 Å. The 
3.0 Å native data set, the UDP, as well as the maltooctaose complex data sets 
were collected on beam line 23-ID at the Advanced Photon Source operated by 
the General Medicine and Cancer Institute Collaborative Access Team. The data 
collected at the 19-ID beamline were indexed, integrated and scaled using the 
program package HKL3000 and the data collected at the 23-ID beamline were 
processed with HKL200084.  
ii. R589A/R592A glucose-6-phosphate co-crystals data set 
 The glucose-6-phosphate co-crystal dataset was collected on beam line 
23-ID at the Advanced Photon Source operated by the General Medicine and 
Cancer Institute Collaborative Access Team and the data was processed with 
HKL200084. 
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2. Structure solution, model building and refinement 
i. R580A/R581A/R583A native 1 structure 
 The R580A/R581A/R583A mutant crystallizes in the primitive monoclinic 
P21 space group with two similar but distinct cell dimensions. The structure of the 
native1 R580A/R581A/R583A was solved using the method of multiple 
isomorphous replacement from two distinct tantalum bromide cluster (Ta6Br12) 
derivatives, combined with 4-fold averaging, solvent density modification and 
iterative partial model phase combination to extend the resolution of the electron 
density maps from 5.5 Å to 3 Å. The intial refinement of the structure was 
performed with the program Refmac5 and subsequent refinements were done 
with PHENIX, which improved the R values by 3-5%. The conjugate gradient 
matrix refinement protocol utilized the maximum likelihood target function and 
NCS restraints for each subunit along with tightly restrained individual 
temperature factor values. 
ii. R580A/R581A/R583A native 2 and ligand complex structures 
The native 2 and ligand complex structures were solved by molecular 
replacement method using the program AMORE and the refined native 1 
structure as the search model. Rigid body refinement of the AMORE solutions 
was performed using the program Refmac5 defining each monomer as the rigid 
body. This was followed by restrained refinement with NCS restraints for 
individual subunits. For the ligand complexes, the resulting maps were used to 
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manually dock the respective ligands using the program Coot and the merged 
structures were subjected to further conjugate gradient matrix refinement with 
Refmac5 and PHENIX using the maximum likelihood target function. The 
monomer libraries for the UDP and maltotetraose molecules were generated 
from the glycogenin (PDB id: 1LL2) and pullulanase (PDB id: 3FAX) structures 
respectively. For the 3.5 Å UDP-complex structure, a single overall B-factor for 
the protein and a separate overall B-factor for the ligands was refined.   
iii. R589A/R592A glucose-6-phosphate complex structure 
The R589A/R592A and R580A/R581A mutants cocrystallized with 
glucose-6-phosphate in the I222 space group. The structure of R589A/R592A 
mutant was solved my molecular replacement using the program AMORE and 
the R580A/R581A/R583A monomer as the search model. Each monomer was 
defined as a rigid body for the rigid body refinement in Refmac5. Subsequent 
restrained refinements were performed with Refmac5 and PHENIX and all 
refinement protocols utilized NCS restraints for each domain (N-terminal domain, 
C-terminal domain and long helical domain) in each subunit.  
F. Structure analysis 
1. Protein surface analysis 
The accessible surface area of the protein was calculated with the 
Areaimol85 program of the CCP4 suite. The analysis of the protein interfaces 
were performed with the Protein Interfaces, Surfaces and Assemblies (PISA)86 
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service at the European Bioinformatics Institute. The buried surface area of the 
tetrameric interface was calculated by treating each dimer of the dimer-of-dimers 
assembly as a single polypeptide. 
2. Domain rotation analysis  
The LSQ-superpose program of the CCP4 suite was used for analyzing 
the domain rotations in the oligomers. For the inter-domain rotation measurement 
in R580A/R581A/R583A, the C-terminal domains of subunit B and D were 
aligned and the rotational matrices for the N domain were generated using the 
above aligned structures. 
The overall conformational change induced by glucose-6-phosphate was 
determined by aligning the long helical domains of the AC dimer of the 
R580A/R581A/R583A and R589A/R592A structures. The changes in the inter 
domain rotations were calculated by superposing the long helices of the 
monomer s and calculating the rotational matrices for the N and C domain 
alignments. 
G. GS activity measurement and data analysis  
1. Preparation of treated glycogen for GS assay 
 The mixed bed resin TMD-8 hydrogen and hydroxide form (Sigma-Aldrich) 
was washed with 5 column volumes of distilled water. A freshly prepared 10% 
solution of rabbit liver glycogen type III (Sigma Aldrich) was applied to the column 
and washed with distilled water to elute glycogen. Glycogen containing fractions 
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(turbid appearance) were pooled and mixed with ice-cold 95% ethanol to a final 
concentration of 66% ethanol. Two drops of 1 M NaCl solution was added to 
facilitate glycogen precipitation and the precipitated glycogen was collected by 
centrifugation at 8,000 rpm for 20 min at 4°C. The glycogen precipitate was 
further washed with 95% ethanol and recollected by using a similar centrifugation 
method. The precipitated glycogen was set to air dry and the dried glycogen was 
ground to coarse powder before dissolving it to 8% w/v solution with distilled 
water. 
2. GS assays 
i. Standard assay 
 Glycogen synthase activity was determined by the method described by 
Thomas et al.32 and quantified my measuring the amount of 14C-glucose 
incorporated from UDP-[14C ]-glucose into glycogen and the assay reactions 
were at 30°C for 15 min. The 10X dilution buffer contains 500 mM Tris-HCl, 200 
mM EDTA, 250 mM KF pH 7.8. 1X GS dilution buffer was prepared by a 10-fold 
dilution of the 10X buffer and inclusion of treated glycogen and DTT to a final 
concentration of 0.1% and 1mM respectively. For the activity determination, the 
Gsy2p stock solution was diluted to 0.02 mg/ml with cold dilution buffer 
containing 20 mM Tris pH 8.0 and 1 mM DTT. The protein was further subjected 
to 1:5 dilution with 1X GS buffer and incubated at RT for 10 min. 25 µL of the 
diluted protein sample was added to 50 µL reaction mix (prewarmed for 10 min at 
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30°C ) and incubated at 30°C for 15 min following which 62.5 µL was spotted on 
the filter paper. After extensive washing with 66% ethanol and drying the 14C 
counts were measured with a scintillation counter. GS activity was measured 
under the standard assay conditions with 6.7 mg/ml glycogen and 4.4 mM UDP-
glucose in the absence or presence of 7.2 mM of glucose-6-phosphate.   
ii. Sulfate titration 
 The sulfate titration was done under the standard assay conditions with six 
different concentrations of Li2SO4 between 0-1 M. A stock solution of 2 M Li2SO4   
pH 7.8 was prepared in 10 mM Tris-HCl pH 7.8 and this was used for preparing 
the reaction mixes for the sulfate titration of Gsy2p. 
iii. Glucose-6-phosphate titration 
 For the glucose-6-phosphate activation, the concentration of glycogen and 
UDP-glucose in the reaction mixes were 6.7 mg/ml and 5 mM respectively and 
the activity was measured in the absence and presence of six concentrations of 
glucose-6-phosphate in the range of 0.03-3 mM.  
iv. UDP-glucose titration 
The UDP-glucose kinetics was measured with reaction mixes containing 
6.7mg/ml of glycogen, and six concentrations of UDP-Glucose in the range of 
0.075-5 mM, either in the presence or absence of saturating concentrations of 
glucose-6-phosphate. 
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v. Glycogen titration 
 For the glycogen titration the enzymes were diluted in 1X GS dilution 
buffer that had no added glycogen. The assays were done with 4.4mM UDP-
glucose in the reaction mixes either in the absence or presence of saturating 
concentrations of glucose-6-phosphate. Nine different concentrations of glycogen 
in the range of 0.03-12mg/ml were used.  
3. Kinetic data analysis 
 Enzyme kinetic data were analyzed using the SigmaPlot software 
package. The UDP-glucose kinetics data were fitted to the Michaelis – Menten 
equation V=Vmax*[S]/(Km+[S]). The glucose-6-phosphate activation data were 
fitted to a three parameter rectangular hyperbola V=V0+ a*x / (b+x), where V0 is 
the rate in the absence of glucose-6-phosphate, x is the concentration of 
glucose-6-phosphate, a is the maximal velocity and b is the concentration of 
glucose-6-phosphate required for half maximal activation (M0.5). The kinetic 
constants were determined from these fits. The glycogen titration data was fitted 
to the standard Michaelis-Menten equation V= a*x / (b+x), where a is the Vmax 
(glycogen varied) and b is the concentration of glycogen required for half maximal 
activity (S0.5). 
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4. Dephosphorylation of phosphopeptide ligated semi-synthetic Gsy2p by 
protein phosphatase treatment 
The phosphopeptide ligated semi-synthetic protein stock solution (3mg/ml) 
was diluted 100-fold with 20 mM Tris pH 7.0. The diluted protein was treated with 
protein phosphatase PP1γ (final concentration 50 μg/ml) for 1 hr at 30°C in the 
presence of 0.2 mM MnCl2. The reaction was terminated by a 10-fold dilution of 
the reaction mix with the 1X GS buffer wherein the EDTA present in the 1X buffer 
chelates the Mn ions required for the catalytic activity of the phosphatase 
enzyme.
56 
 
RESULTS 
A. Expression and purification of recombinant Gsy2p 
1. Purification of His-tagged full length Gsy2p 
His-tagged Gsy2p was expressed in E.coli BL21-DE3 cells and purified 
from the cell lysate by Ni2+ affinity chromatography followed by ion exchange 
chromatography on Q-sepharose. Typical protein yields from 6L bacterial culture 
were 25-30 mg and the yields were consistent amongst the wild type and 
different mutants. The final Q-pool was greater than 90% pure as analyzed by 
Coomassie staining on a SDS-PAGE gel (Figure 18). All protein concentrations 
were measured using the Biorad protein assay kit with bovine serum albumin as 
the standard. 
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Figure 18. Representative SDS-PAGE gels of His-tagged Gsy2p Prep.  
Top panel. Ni-NTA Column purification of R580A/R581A/R583A Gsy2p. Bottom 
Panel. Q-Sepharose column purification of of R580A/R581A/R583A Gsy2p. 
Typical yield from 6L prep was ~25-30 mg protein. 
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2. Purification of truncated and semi-synthetic Gsy2p 
The Gsy2p Mxe GyrA Intein-CBD fusion protein was expressed in E.coli 
ER2566 cells and affinity purified from cell lysate using chitin resin. Overnight 
cleavage with 50mM DTT at room temperature resulted in ~ 6 mg of truncated 
protein from 2 L culture. Cleavage and coupling with 2% thiophenol and 1 mM 
synthetic peptide gave a typical yield of ~3-5 mg of semi-synthetic protein from 
2L culture. Analysis of the His-tagged full length, 640 truncated and peptide 
ligated semi-synthetic proteins on a 7% SDS-PAGE gel showed clear shift in the 
position of the protein bands (Figure 19). 
 
Figure 19. Semi-synthetic Gsy2p Prep and Mobility shift of Gsy2p.  
Left Panel. 8% SDS-PAGE gel of Chitin Resin Purification and Coupling of 35mer 
Phosphopeptide to wild type Gsy2p. Right Panel. 7% SDS-PAGE gel of Wild 
type, 640 Truncated and Synthetic peptide ligated Gsy2p.  
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B. Specific activity, activity ratio and UDP-glucose and glucose-6-
phosphate kinetics of Gsy2p 
All the kinetic measurements are the average from at least three separate 
experiments where assays were performed in duplicate for each individual 
experiment. With the exception of the semi-synthetic single (R580A) and double 
(R580A/R581A) arginine mutants, the results represent assays from at least two 
different protein preparations. The wild type recombinant Gsy2p has a basal 
activity of 1.03 mmol.min-1 with an activity ratio of 0.6. Consistent with the earlier 
work, both the triple alanine mutants are insensitive to glucose-6-phosphate 
activation and exhibit 35 to 45% decrease in the basal activity (Table 1).  
To delineate the role of the conserved arginines in mediating inhibition by 
phosphorylation, we used the expressed protein ligation approach to ligate 
synthetic phosphopeptides and non-phosphopeptides to constructs of Gsy2p 
truncated at residue 641 with either wildtype sequences or mutated sequences 
within the arginine cluster. The sequence for the fusion peptides was identical to 
the wild type Gsy2p for residues 643 through 676 (35mer) or 643 through 690 
(49 mer) with or without a phosphothreonine at position 668. Since an N-terminal 
cysteine residue is required for ligating synthetic peptides in the intein mediated 
peptide ligation approach, a non-conserved lysine in the wild type enzyme at 
position 642 was replaced by cysteine in the semi-synthetic proteins. Gsy2p 
truncated at residue 641 and the control non-phosphorylated peptide-ligated 
enzymes exhibit activities and activity ratios similar to the recombinant wild type 
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enzyme. In contrast, introduction of a single phosphothreonine at position 668 in 
the peptide-ligated construct inhibits the enzyme in a manner comparable to the 
wild type enzyme phosphorylated by the Pho85p/Pcl10p complex62. Ligation of 
the 35mer phosphopeptide to the wild-type enzyme decreases the basal activity 
by 70% and reduces the activity ratio about four-fold. Ligation of the 49-mer 
phosphopeptide decreases the basal activity of the enzyme by 90%.  
Incubation of the phosphopeptide ligated samples with the protein phosphatase 
PP1 restored the activity ratio of the enzymes to that of the control non-
phosphopeptide ligated enzymes.  
The influence of phosphate on substrate and activator binding was studied 
by titrating Gsy2p with UDP-glucose and glucose-6-phosphate (Table 2). In both 
the basal and activated states, the wild-type full-length and truncated forms 
exhibit similar KM [UDP-Glu] and M0.5 values for glucose-6-phosphate. However 
the KM [UDP-Glu] of the phosphorylated form in the basal state is five times 
higher than that of the wild type enzyme and upon activation by glucose-6- 
phosphate, is restored to the wild-type values. The concentration for half maximal 
activation (M0.5) by glucose-6-phosphate for the phosphorylated enzyme was 
three times that of the wild type enzyme. 
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Table 1. Specific activity and activity ratio of Gsy2p 
 
GS activity was measured in the presence of 6.7mg/ml of glycogen and 4.4 mM 
UDP-glucose in the absence and presence of 7.2 mM glucose-6-phosphate.  The 
errors indicate the S.E.M. from three independent experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enzyme 
Synthase Specific activity  
(mmol. min-1) 
Activity 
Ratio 
-G6P/+G6P 
 
No G6P 7.2 mM G6P 
Wild Type 1.03 ± 0.03 1.73 ± 0.03 0.60 ± 0.01 
Wild type-640 Truncated 1.25 ± 0.04 1.95 ± 0.05 0.64 ± 0.01 
Wild type-35mer 
Nonphosphopeptide ligated 
1.12 ± 0.02 1.77 ± 0.05 0.63 ± 0.01 
Wild type-35mer 
Phosphopeptide ligated 
0.27 ± 0.02 1.96 ± 0.04 0.14 ± 0.01 
PP1 Treated Wild type-35mer 
Phosphopeptide ligated 
1.18 ± 0.02 2.04 ± 0.08 
 
0.58 ± 0.01 
Wild type-49mer 
Nonphosphopeptide ligated 
1.08 ± 0.02 1.78 ± 0.02 0.61 ± 0.02 
Wild type-49mer 
Phosphopeptide ligated 
0.10 ± 0.01 1.92 ± 0.04 0.05 ± 0.01 
PP1 Treated Wild type-49mer 
Phosphopeptide ligated 
1.34 ± 0.03 
 
2.17 ± 0.02 
 
0.62 ± 0.01 
 
R580A/R581A/R583A 0.55 ± 0.02 0.51 ± 0.03 1.09 ± 0.02 
R587A/R589A/R592A 0.66 ± 0.01 0.58 ± 0.02 1.14 ± 0.05 
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Table 2. UDP-glucose and glucose-6-phosphate kinetic parameters of 
Gsy2p 
 
Enzyme KM [UDP-Glucose] mM M(0.5) G6P 
mM -G6P +G6P 
Wild type-Full length 0.54 ± 0.03 0.28 ± 0.02 0.04 ± 0.004 
Wild type-641 truncated 0.62 ± 0.05 0.35 ± 0.03 0.05 ± 0.006 
Wild type-T667 35mer 
Phosphopeptide ligated 
2.4 ± 0.40 0.45 ± 0.06 0.13 ± 0.004 
Wild type-T667 49mer 
Phosphopeptide ligated 
ND ND 0.12 ± 0.002 
 
ND – Not Determined 
UDP-glucose titration. GS activity of the wild-type and Thr668 phosphopeptide 
ligated  semisynthetic wild type Gsy2p were measured in the presence of 6.7 
mg/ml of glycogen and six concentrations of UDP-glucose in the range of 0.075-
5mM in the absence or presence of 7.2 mM glucose-6-phosphate. The data was 
fitted to the Michaelis – Menten equation V=Vmax*[S]/(Km+[S]) to extract the KM 
values. 
 
Glucose-6-phosphate titration. GS activity was measured in the presence of 6.7 
mg/ml of glycogen, 5 mM UDP-Glucose and seven different concentrations of 
glucose-6-phosphate in the range of 0-3 mM. Data was fitted to a three 
parameter rectangular hyperbola V=V0+ a*x/(b+x) to calculate the AC50 for 
glucose-6-phosphate. The errors indicate the S.E.M. from three independent 
experiments 
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C. Crystallization and data collection of Gsy2p 
It was observed that Gsy2p purified from fresh unfrozen cell pellets 
resulted in better diffraction quality crystals. Since 95% of the 
R580A/R581A/R583A crystals were physically twinned, the seeding method was 
used to improve the quality of the crystal. Microseeding of Gsy2p 
R580A/R581A/R583A mutant with the initial six-sided plate crystals resulted in 
200 µm trapezoidal crystals that diffracted to about 3.0 Å. The triple mutant 
crystallized in two different crystal forms that belong to the same space group but 
differed slightly in the cell parameters (Table 2). The different crystal forms could 
not be differentiated visually and were identified during data collection and 
processing. The tantalum derivatives were prepared by soaking the triple mutant 
crystals. Upon incubation for six hours the tantalum bromide soaked crystals 
turned emerald green while the surrounding liquid became less colored and this 
property was used as an estimate for derivatization. 
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Figure 20. Gsy2p crystals. 
(a) Primitive monoclinic crystal of Gsy2p R580A/R581A/R583A mutant in the P21 
space group. (b) I centered orthorhombic crystals of of Gsy2p R589A/R592A 
mutant in the I222 space group. 
 
The glucose-6-phosphate complex crystals of R589A/R592A mutant 
diffracted to 2.4 Å and crystals were formed only when the protein was co-
crystallized with glucose-6-phosphate (minimum concentration of 25 mM). All the 
Gsy2p data sets were collected at the Synchrotron facility at the Advanced 
Photon source and the data collection statistics are summarized in Table 3.
a b 
  
Table 3. Data collection statistics 
Data set 
R580A3 
Native1 
R580A3 
TaBr1 
R580A3 
TaBr2 
R580A3 
Native 2 
 
R580A3 
UDP 
R580A3 
Malto 
dextran 
 
R589A2 
G6P 
Space group P21 P21 P21 P21  P21  P21  I222 
Cell Dimensions        
   a  (Å) 
   b  (Å) 
   c  (Å) 
96.5 
166.1 
121.0 
97.3 
167.6  
122.2 
96.5 
167.3  
121.6 
93.9 
161.8 
121.6 
96.6 
167.2 
121.2  
96.6 
166.7 
121.1  
192.7 
206.9 
205.8 
   α (°) 
   β (°) 
   γ  (°) 
90.0 
103.4 
90.0 
90.0 
103.3 
 90.0 
90.0 
103.1 
 90.0 
90.0 
103.1 
 90.0 
90.0 
102.7 
 90.0  
90.0 
103.2 
 90.0  
90.0 
 90.0 
 90.0 
Resolution (Å) 
50-3.0 
(3.1-3.0) 
50.0 - 4.5 
(4.6 -4.5) 
50.0-4.5 
 (4.6-4.5) 
50-2.9  
(2.95-2.9) 
50.0-3.5  
(3.57-3.51)  
50.0-3.0 
(3.05-3.0)  
50.0-2.4 
(2.44-2.40) 
Rmerge(%) 8.2 (47.5) 10.9 (46.9) 12.5 (37.8) 8.7 (68.7) 11.0 (44.4) 8.4 (52.5) 8.7 (55) 
I /σI 13.5 (2.1) 14.7 (1.7) 7.5 (1.9) 17.1 (2.3) 9.9 (1.7) 13.2 (2.0) 13.9 (2.0) 
Completeness (%) 99.6 (96.8) 92.8 (94.7) 82.7 (64.1) 99.0 (98.7) 99.0 (92.7) 99.4 (94.7) 98.5 (79) 
Redundancy 3.7 (2.6) 2.9 (2.6) 3.3 (3.4) 4.7 (4.5) 3.6 (2.7) 3.8 (3.1) 4.8 (3.1) 
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D. Structure solution of R580A/R581A/R583A Native1 
1. Phasing multiple isomorphous replacement method 
Gsy2p structure was solved using a native and two tantalum cluster 
derivative datasets of the R580A/R581A/R583A mutant. The derivatives 
diffracted to 4.5 Å and the Harker section of the isomorphous difference 
Patterson map generated with the native and derivative data sets showed clear 
peaks. 
 
 
Figure 21. Isomorphous difference Patterson map.  
Harker section of the Isomorphous Difference Patterson Maps at 5.5 Å generated 
with the Native1 and TaBr1 datasets. The x,y,z positions of the four common 
sites are marked in red. 
 
The program SOLVE87,88 was used to calculate the initial phases and the 
hexatantalum tetradecabromide compound was considered as a single tantalum 
site for the analysis. Although the derivatives diffracted to 4.5 Å, the isomorphous 
difference signal decreased significantly below 5.5 Å and hence the initial 
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phasing was done between 25 and 5.5 Å. Four common sites were identified in 
both the derivatives and a fifth site with lower occupancy was identified in one of 
the derivatives. The positions of the four common sites could be solved manually 
from the Harker peak positions. Together these derivatives provided phase 
information with a mean FOM of 0.47 and a Z-score of 43.8.  
 
Table 4. Heavy atom solution from SOLVE  
 
Site Co-ordinate Position TaBr1 TaBr2 
X Y Z Occup H/Sig Occup H/Sig 
1  0.601  1.000  0.424   0.86   9.8   0.84   10.0  
2  0.353  0.730  0.118   1.04  12.0   0.88   12.0  
3  0.351  0.802  0.337   0.98  12.4   0.94   13.7  
4  0.594  0.532  0.113   0.75  10.0   0.75   10.1  
5 0.799  0.565  0.519   0.20    2.8  -  -  
 
The associated program RESOLVE identified a non-crystallographic 2-fold 
symmetry axis based on the tantalum sites and used the NCS averaging and 
density modification to provide an electron density map to 5.5 Å with a FOM of 
0.74. These phases were sufficient to visually locate the biological tetramer 
within the asymmetric unit and the symmetry relationships amongst the 4 
common tantalum sites in the two derivatives provided the location of the three 2-
fold axes that define the tetramer. 
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Figure 22. Gsy2p (R580A/R581A/R583A) phasing by multiple isomorphous 
replacement method.  
(a) 2-fold averaged, 5.5 Ǻ electron density map from RESOLVE. The four 
common tantalum cluster sites are highlighted. (b) 2-fold averaged, 5.5 Ǻ 
electron density map from RESOLVE. The four common tantalum cluster sites in 
the tetramer highlighted. (c) 4-fold averaged, density modified 5.5 Ǻ electron 
density map from RESOLVE. FOM 0.73 (d) 4-fold averaged, density modified, 
phase extended 3.0 Ǻ electron density map from DM. 
 
RESOLVE was rerun using explicit rotation matrices defining the 4-fold 
NCS relationships to provide phases to 5.5 Å with a mean FOM of 0.73. The 
electron density map produced using these phases clearly showed the presence 
of a tetramer in the asymmetric unit and showed good density for many α-helices 
but the β-sheets were less well defined. Phase extension to 3.0 Å was 
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accomplished using the program DM as implemented in the CCP4 suite89. This 
phase extension protocol utilized a total of 250 steps from 6.0 to 3.0 Å and the 
same 4-fold averaging matrices utilized by RESOLVE. The resulting 3.0 Å 
electron density map was marginally interpretable, but the general relationship of 
the protein fold to the bacterial glycogen synthase enzymes could be identified. 
2. Phase extension by phase combination approach 
To improve the map quality, we used the phase combination approach 
implemented in the program Phenix90,91 (“maps_only” subroutine). A partial 
model of the yeast Gsy2p monomer was generated by docking elements of the 
secondary structure from a polyalanine model of the Agrobacterium GS 
monomer (PDB code 1RZU) into a single subunit within the 3.0 Å electron 
density map. The tetramer was generated by applying the NCS operators to this 
partial monomer structure. The phase information from this partial model and the 
experimental phase information from SOLVE were combined to extend the 
usable phases from 5.5 to 3.0 Å. Two iterations of phase combination with 
increasingly larger partial models within the program Phenix produced phases 
that yielded a completely interpretable 3.0 Å electron density map, from which a 
poly-alanine model of the protein was completely rebuilt using the graphics 
program COOT92. A structure based sequence alignment of the glycogen 
synthases was used to assist the sequence assignment to the initial poly-alanine 
model.  
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Figure 23. Schematic representation of the phase extension approach.  
The current electron density maps from DM and RESOLVE were used to 
generate a partial model of Gsy2p, which was refined against the native data set. 
The phase information from this refined model and the experimental phase 
information (isomorphous heavy metal signal from SOLVE) were combined to 
give a phase combined map, which was further subjected to 4-fold NCS 
averaging and solvent flattening to generate the new electron density map. Two 
iterations of the phase combination approach resulted in a completely 
interpretable 3.0 Å electron density map. 
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E. Refinement of Gsy2p structures 
All the refinement protocols utilized NCS restraints for each subunit or 
each domain of the subunits. The two R580A/R581A/R583A structures were 
refined to 3.0 and 2.9 Å and final Rwork / Rfree values of 20.3/25.4 and 22.1/26.1. 
The glucose-6-phosphate bound activated conformation of the R589A/R592A 
mutant structure was refined to Rfree = 24.3% and Rwork = 20.3% (Table 5) . The 
asymmetric unit of both the crystals contain a tetramer. The triple mutant 
structures contain residues 2 to 639 with three major breaks, where the density 
was not sufficient to build the model. These disordered regions showed clear 
density in the glucose-6-phosphate activated conformation. In addition, chains B 
and C in the activated conformation structure exhibited clear electron density for 
an additional seven residues at the C-terminus. All the final models displayed 
good stereochemistry as analyzed by the program PROCHECK93.  
 
 
 
 
 
 
 
 
 
  
Table 5. Data collection statistics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data  
R580A3 
Native1 
R580A3 
Native 2 
 
R580A3 
UDP 
R580A3 
Malto 
dextran 
 
R589A2 
G6P 
Resolution (Å) 3.0 2.9 3.5 3.0 2.4 
No. reflections 70557 80301 46330 73079 148274 
Rwork / Rfree(%) 20.3/25.4 22.1/26.1 21.4/24.4 20.9/24.7 20.3/24.3 
No of atoms      
    Protein 19770 19703 19707 19742 20818 
    Ligand/ion 80 75 160 260 124 
B-factors      
    Protein 64.37 70.29 103.90 82.10 57.41 
    Ligand/ion 90.05 90.50 130.72 112.14 47.11 
R.m.s deviations      
 Bond lengths (Å) 0.008 0.009 0.009 0.008 0.009 
Bond angles  (°) 1.07 1.17 1.12 1.15 1.15 
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F. Structure of Gsy2p R580A/R581A/R583A 
The asymmetric unit of the native 1 R580A/R581A/R583A crystals 
contains a single tetramer and the final refined protein model contains residues 
2-205, 208-277, 285-401, 414-540 and 546-639. The C-terminal 65 residues, 
which contain the regulatory phosphorylation sites, are not observed in the 
structure. SDS-PAGE analysis of the crystals reveals that less than 10% of the 
protein in the crystal has been proteolyzed. This suggests that the C-terminal 
region of the yeast Gsy2p is crystallographically disordered, rather than 
selectively proteolyzed during crystallization. This is consistent with predictions of 
intrinsic disorder by the program PONDR®94 that identifies the final 80 residues 
as having a high probability of disorder. 
1. Overall fold and oligomeric arrangement 
Like other GTB family members, the yeast Gsy2p monomer folds into two 
structural domains dominated by their individual Rossmann-folds, each with a 
central six-stranded parallel β−sheet flanked on either side by α-helices. The N-
terminal Rossmann domain has two inserts, one between the strands β2 and  
β5, and the other between β7 strand and α10 helix (Figure 24). The polypeptide 
crosses between the two domains with the linker peptide consisting of strand β9, 
and helices α12 and α13, which together form one of the two inter-domain 
connections. The second inter-domain connection is made upon exit of the C-
terminal Rossmann domain where the two long helices (α22 and α23) form a 
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characteristic feature of GT-B glycosyl transferases with these inter-domain 
helices. The C-terminal Rossmann domain of all eukaryotic synthases has a 
unique insert between strand β11 and helix α17 (Figure 24). This insert’s major 
structural feature is a pair of long helices that extend away from the Rossmann-
fold and form the majority of the inter-subunit interface. The cluster of conserved 
arginine residues found in eukaryotic synthase enzymes is located in the first of 
the two inter-domain helices (α22), which we will refer to as the regulatory helix, 
in consideration of the regulatory nature of these arginine residues.  Lastly, a 
small, unidentified, fragment of polypeptide between 4-6 residues long is present 
within the substrate-binding cleft of monomers C and D. These could be either  
residues comprising the N-terminal His-Tag extension from the symmetry related 
monomers A and B which are positioned 18Å away, or a short region of the 
disordered C-terminal extension. There is insufficient electron density for 
unambiguous sequence assignment of these residues, hence they have been 
modeled as a stretch of poly-alanine residues. 
The most striking feature of the yeast Gsy2p is the tetrameric arrangement 
of the subunits, and relatively limited intersubunit contact surface between the 
two dimers that comprise the enzyme’s dimer-of-dimers arrangement. The 
primary subunit interface is formed by the coiled-coil helical arrangement of 
helices α15 and α16, which represent the unique insertion in the C-terminal 
Rossmann domain (residues 365-431). A 12 amino acid loop between these two 
helices (residues 401-412) is disordered and not visible in the 
R580A/R581A/R583A structures. 
  
 
Figure 24. Structure of Gsy2p monomer.  
(a) Topology diagram of the protein fold of Gsy2p. (b) Ribbon representation of the structure of Gsy2p monomer. The 
conserved secondary structural elements of the core Rossmann domains are represented in purple and cyan, the linker 
region in yellow and the unique eukaryotic inserts in blue and green. 
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The major interaction between dimer pairs is made by the C-terminal 
region of helix α15 and the loop region that connects the linker peptide helix α15 
with the β10 strand of C-terminal Rossmann domain (Figure 25). The dimer 
interace is formed by the association of helix α16 of one monomer with helix α2 
and the loop connecting the strands β4 and β5 of the other monomer.  
 
 
 
Figure 25. Dimer arrangement of Gsy2p.  
Ribbon representation of the structure of Gsy2p dimer with the bound sulfates 
represented as space filling models. Different colors represent individual subunits 
and the regulatory helix is shown in cyan. 
 
  
 
Figure 26. Tetramer arrangement of GSy2p. 
Ribbon representation of Gsy2p R580A/R581A/R583A tetramer with the bound sulfates in space filling models. Different 
colors are used to represent different subunits and the regulatory helices are shown in cyan. 
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2. Arginine cluster 
The regulatory helices (α22) containing the arginine cluster are located 
across from one another along opposing sides of one of the molecular 2-fold 
axes in the tetramer and the orientation of the helical axis is orthogonal to the 
helical bundles forming the tetrameric interface (Figure 26). A surface pocket is 
present in the N-terminal region of the regulatory helix in the proximity of the side 
chains of the residues 583 and 587 (3rd and 4th arginines of the conserved 
cluster), which are pointing towards this cavity (Figure 27b). Due to the position 
of these key arginines and the mixed hydrophilic and hydrophobic nature of the 
cleft, we hypothesized that this cleft forms the glucose-6-phosphate binding 
pocket and these two arginines are likely involved in hydrogen bonding or 
electrostatic interactions with the phosphate group of glucose-6-phosphate.  
To test this hypothesis we reintroduced Arg 583 and Arg 587 into their 
respective triple arginine mutants, forming the R580A/R582A and R588A/R592A 
double mutants, and tested their glucose-6-phosphate sensitivity. Reintroduction 
of either arginine into their respective triple mutants restored glucose-6-
phosphate sensitivity (Table 6).The R588A/R592A double mutant displayed 
specific activities and activity states similar to those of the wild-type 
phosphorylated enzymes (Table 6).  
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Figure 27. Arginine cluster and glucose-6-phosphate binding pocket of 
Gsy2p. 
(a) Ribbon diagram of Gsy2p highlighting the regulatory helices at the dimer-
dimer interface. (b) Ribbon diagram and molecular surface representation of the 
Gsy2p monomer highlighting the glucose-6-phosphate binding pocket (black 
arrow). The three alanines and arginines at the interface are labeled. 
 
 
To study the role and influence of the arginine residues in phosphorylation 
mediated inhibition, we used the peptide ligation approach to create 
semisynthetic phosphorylated proteins of the mutants and tested their activity. 
Both the triple arginine mutants were nearly insensitive to inhibition by 
phosphorylated Thr668 and exhibit similar activities after ligation to both the 
35mer and 49mer phosphopeptides. Interestingly, the activity ratios of the 
peptide-ligated constructs were inversely correlated with the number of arginines 
residues in this first cluster, with the R580A/R581A mutant having the highest 
activity ratio and the wild-type sequence the lowest activity ratio. 
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Table 6. Specific activity and activity ratio of Gsy2p arginine mutants 
  
 
 
GS activity was measured in the presence of 6.7mg/ml of glycogen and 4.4 mM 
UDP-glucose in the absence and presence of 7.2 mM glucose-6-phosphate.  The 
errors indicate the S.E.M. from three independent experiments 
 
 
 
Enzyme 
Synthase Specific activity  
(mmol. min-1) 
Activity 
Ratio 
-G6P/+G6P 
 
No G6P 7.2mM G6P 
Wild Type 1.03 ± 0.03 1.73 ± 0.03 0.60 ± 0.01 
R580A 0.99 ± 0.01 1.55 ± 0.03 0.64 ± 0.01 
R580/R581A 1.07 ± 0.05 1.59 ± 0.05 0.67 ± 0.02 
R580A/R581A/R583A 0.55 ± 0.02 0.51 ± 0.03 1.09 ± 0.02 
R587A/R589A/R592A3 0.66 ± 0.01 0.58 ± 0.02 1.14 ± 0.05 
R589/R592A 0.17 ± 0.01 1.56 ± 0.07 0.11± 0.01 
Wild type-35mer 
Phosphopeptide ligated 
0.27 ± 0.02 1.96 ± 0.04 0.14 ± 0.01 
R580A/R581A/R583A -35mer 
Phosphopeptide ligated 
0.47 ± 0.01 0.44 ± 0.01 1.05 ± 0.02 
R587A/R589A/R592A-35mer 
Phosphopeptide ligated 
0.41 ± 0.01 0.39 ± 0.02 1.04 ± 0.05 
Wild type-49mer 
Phosphopeptide ligated 
0.10 ± 0.01 1.92 ± 0.04 0.05 ± 0.01 
R580A-49mer Phosphopeptide 
ligated 
0.34 ± 0.02 1.74 ± 0.10 0.20 ± 0.01 
R580A/R582A-49mer 
Phosphopeptide ligated 
0.58 ± 0.01 1.50 ± 0.01 0.39 ± 0.01 
R580A/R581A/R583A -49mer 
Phosphopeptide ligated 
0.43 ± 0.01 0.42 ± 0.01 1.04 ± 0.04 
R587A/R589A/R592A-49mer 
Phosphopeptide ligated 
0.38 ± 0.01 0.35 ± 0.01 1.09 ± 0.09 
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G. Allosteric activation of Gsy2p – Structure of R589A/R592A 
1. Glucose-6-phosphate binding 
The activated conformation of Gsy2p was obtained by co-crystallizing the 
R589A/R592A mutant with glucose-6-phosphate. Glucose-6-phosphate is bound 
in all the four subunits of the tetramer in the putative glucose-6-phosphate 
binding cleft located between the regulatory helix (α22) and helix α13. The side 
chains of residues His 286, Lys 290, His 500, Arg 583, Arg 587 and Arg 580 form 
hydrogen bonding interactions with the 6-phosphate group of the activator 
(Figure 28). The glucose ring is positioned in such a way that the C1’ hydroxyl 
group forms a hydrogen bond with the side chain of Gln 283 from one subunit 
and the C2’ hydroxyl group hydrogen bonds with the His280 from the opposing 
subunit. In addition, the C6’ and O5 oxygen atoms of the glucose ring interact 
with the side chain of Arg 587. The C2’ hydroxyl is also an average of 3.7 Å from 
the side chain of Asn 284. The faces of the glucose ring are held between the 
side chains of Ala 287 and Ile 584. 
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Figure 28. Glucose-6-phosphate binding in Gsy2p.  
Ribbon representation of Gsy2p with the bound glucose-6-phosphate and the 
interacting residues in ball-and-stick model. Different colors are used for 
representing different subunits. The map shown is the original 2fo-fc electron 
density map for the bound glucose-6-phosphate (contoured at 1 s.d of the map). 
The interacting residues are labeled (the prime sign (‘) indicates the residues 
from second subunit) and the hydrogen bonding interactions are represented as 
dashed green lines. 
2. Conformational changes induced by Glucose-6-phosphate 
Binding of glucose-6-phosphate induces an ordering of the structure for 
the loop connecting helix α13 to the first strand (β10) of the C-terminal 
Rossmann domain – residues 277-284 (Figure 29b). The ordered loop stabilizes 
the activated conformation by interacting with the glucose-6-phosphate and side 
chain residues of the partner subunit and increasing the relative distances of the 
regulatory helices from each other by 3.4 Å. The major interactions stabilizing 
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this interface include the aforementioned interactions between His 280 and the 
C2’ hydroxyl of glucose-6-phosphate, hydrogen bonds between the equivalent 
side chains of Asn284 and an interaction between Arg 581 and the main chain 
carbonyl oxygen atoms of residues 276 and 277.   
 
 
 
Figure 29. Glucose-6-phosphate binding induced conformational change at 
the dimer interface.  
Ribbon representation of the regulatory helix dimer interface of Gsy2p with the 
bound sulfate (panel a – R580A/R581A/R583A) and glucose-6-phosphate (panel 
b – R589A/R592A) in space fill models. The region between residues 277 and 
285 that is ordered upon glucose-6-phosphate binding is shown in green.    
 
To analyze the conformational transition induced by glucose-6- phosphate 
binding, we used the native-1 structure of the R580A/R581A/R583A Gsy2p as 
the basis upon which to describe the changes associated with the activated 
conformation of the R589A/R592A double mutant. Due to the complexity of the 
motions, the analysis will divide each subunit into three structural domains – the 
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N-terminal Rossmann domain (residues 2-272), the C-terminal Rossmann 
domain (residues 312-357, 453-577) and the long intersubunit helices (residues 
365-399, 416-434). 
 When the two structures are superimposed using only the intersubunit 
helices for the AC dimer pair, the BD dimer pairs in the two structures are 
displaced by an overall translation of 14.2 Å combined with a 7° rotation (Figure 
30). 
 
Figure 30. Glucose-6-phosphate induced rotational and translational 
motions. 
 Ribbon representation of the aligned long helices of Gsy2p in the two 
conformations highlighting the glucose-6-phosphate induced translational (a) and 
rotational movements (b) Alignment was generated by superimposing the long 
helices of the a and C subunits using the LSQ-superpose program. Different 
colors are used to represent different monomers and the light and dark shades 
are used to represent the R580A/R581A/R583A and R589A/R592A structures 
respectively. The translational and rotational movements are marked by black 
arrows.  
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Within each monomer, the binding of the activator induces a rotation of 
8.5° of the C-terminal Rossmann domain when the intersubunit helices are 
aligned to form a basis for comparison (Figure31). In addition to the rotation of 
the C-terminal domain, the N-terminal Rossmann domain is also rotated away 
from the central interface by an additional 4.5° (Figure 31).   
 
Figure 31. Glucose-6-phosphate binding induced conformational change in 
the Gsy2p monomer.   
Ribbon representation of the superposed basal state and activated state 
monomers. Different colors represent different conformations ( violet – 
R580A/R581A/R583A and Teal – R589A/R592A). (a) The alignment was 
generated by superposing the long helices of chain A (residues 365-399 and 
416-434) of both the conformations using the superpose program of the CCP4 
suite. (b) Alignment was generated by superposing the C-terminal Rossmann 
domain of R580A/R581A/R583A chain A (residues 312-357 and 453-577) with 
the long helix aligned chain A of R589A/R592A. 
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 In additional to the rotation of the Rossmann domains, the other major 
change observed at the dimer (AD) interface is in the positions of helix α16 and 
the loop connecting strand β16 and helix α18 (loop β16-α18) . In the 
R580A/R581A/R583A structure, the β16- α18 loops are located at one of the 
molecular 2-folds and contact each other, while the α16 helix forms interactions 
with strand β3 and helix α2 within the unique sequence insertion found in the N-
terminal Rossmann domain. Activation by glucose-6-phosphate induces a 
translation of the α15 and α16 helices toward the center of this interface, moving 
the β16- α18 loops away from the local 2-fold axis and forming new interactions 
with helices α15 and α16 from the opposing subunit. This translation, coupled 
with the rigid-body rotations of the subunits away from the central interface 
disrupts the interactions between α16 and the N-terminal domain, thereby 
releasing the N-terminal domain and active site from constraining interactions 
with the C-terminal domain of its partner subunit (Figure 32). 
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Figure 32. Glucose-6-phosphate binding induced conformational change in 
the AD dimer.   
Ribbon representation of the AD dimer pair in the basal state and activated state 
(b) with the bound glucose-6-phosphate in space filling model. The β16-α18 and 
β2-α2 loops are highlighted in purple. 
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H. Substrate Binding in Gsy2p 
1. UDP-binding pocket 
 UDP binds to Gsy2p- R580A/R581A/R583A within the large inter-domain 
cleft that separates the two Rossmann-fold domains and interacts with residues 
within the C-terminal domain. The UDP binding pocket is defined by helices 
α18,  α19 and the loops between β16−α19,  β15−α18 and  β10−α14. The uridine 
ring is stacked between the aromatic side chains of Phe 480 and Tyr 492 and the 
4-oxo group of the uridine ring is positioned to form a hydrogen bond with the 
main chain nitrogen atom of Leu481. The ribose ring is positioned within 
hydrogen-bonding distance to the conserved residue Glu 517 such that the side 
chain appears to interact with both the 2’ and 3’ hydroxyls of the ring. The 
phosphate groups of the UDP appear to interact with residues Arg 320, Lys 326, 
Thr 514 and the main-chain atoms of residues Tyr 513 and Thr 514. The strictly 
conserved residue Glu 509, which is proposed to be the catalytic nucleophile, is 
also in close proximity to the bound UDP molecule. 
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Figure 33. UDP binding in Gsy2p.  
Ribbon representation of the Gsy2p UDP binding pocket with the bond UDP and 
interacting residues in ball and stick model. The map shown is the original 2Fo - 
Fc electron density map for the bound UDP (contoured at 1 s.d of the map). The 
residues involved in binding are labeled. 
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2. Maltodextran binding pocket 
 The structure of the Gsy2p complex with maltodextran was solved in the 
P21 space group to a resolution of 3 Å. We observe two binding sites for 
maltodextrans in each subunit – one on the surface of the N-terminal domain 
(site 1) and the other (site 2) is located in a crevice near the dimer interface in the 
C-terminal domain that defines the structural boundary between the conserved 
catalytic core of the enzyme and the unique sequence insertion that forms the 
oligomerization interface (Figure 40c). In each of the two maltodextran binding 
sites, we observe four ordered glucose residues bound within depressions on the 
surface of the enzyme that are lined with residues that are conserved amongst 
eukaryotic GS enzymes.  
Helix α4  is located adjacent to the 1’ end of the maltodextran moiety in the 
N-terminal domain of Gsy2p. The α4 helix is a unique secondary structural 
element present in all the eukaryotic enzymes and is involved in defining one 
side of site 1 in Gsy2p. The remainder of the site is contributed by residues within 
helix α5 which forms the base of the maltodextran site and runs more or less 
parallel with the carbohydrate moiety and the helix α6. Residues Trp 118, Tyr 
145, Trp 149 and Ile184 form the hydrophobic pocket in which the glycan 
residues reside. Hydrogen bonding interactions between the glucose polymer 
and the enzyme are mediated by the side chains of Glu 117, Asp 121, Glu 153, 
Arg182 and Arg 86. The site 1 region on the C and D subunits are utilized in 
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crystal packing contacts and are unavailable to interact with maltodextran in this 
lattice.   
 
 
Figure 34. Maltodextran binding sites in Gsy2p.  
Ribbon representation of the Gsy2p Maltodextran binding site 1(a) and site 2(b) 
with the bond Maltose polymer and interacting residues in ball and stick model. 
The map shown is the original 2fo - fc electron density map for the bound UDP 
(contoured at 1 s.d of the map). The residues involved in binding are labeled. 
The residues selected for mutation are circles in green. 
 
The second maltodextran binding site is located in the C-terminal domain 
at the structural boundary between the long helices that form the oligomeric 
interface and the C-terminal Rossmann-domain. The orientation (1’ to 4’) of the 
maltodextran moiety is essentially anti-parallel to the direction of the beta-strand 
lying on top of the C-terminal Rossmann-domain. The inner surface of this site is 
lined by a hydrophobic stretch of residues between Leu 439 and Val 443, as well 
as Phe 465. This hydrophobic pocket is surrounded by residues Thr 365, Glu 
367, Asn 446, Asp 450 and Arg 460 which provide hydrogen bonding interactions 
with the bound glucose polymer. 
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To test the influence of these maltodextran binding sites on Gsy2p activity, 
we created two triple alanine mutants; W118A/W149A/H156A for site 1 and 
D450A/R460A/F465A for site 2 and compared the kinetic properties of the 
mutants with the wild-type Gsy2p (Figure 35 and Table 7). When compared to 
the wild-type Gsy2p the specific activity of the mutants decreased by 
approximately three to five fold in the presence or absence of glucose-6-
phosphate. Kinetic analysis with varying concentrations of glycogen showed that 
in the absence of glucose-6- phosphate, the Vmax of the mutants decreased five 
times when compared to the wild type. With saturating glucose-6-phosphate, this 
decrease was comparatively less - about 1.5 times. In the absence of glucose-6-
phosphate, the S 0.5 for glycogen increased from 0.25 mg/ml for the wild type to 
about 2 mg/ml for the mutants. Interestingly, in the presence of glucose-6-
phosphate, the S 0.5 for glycogen was decreased for the wild type, whereas it was 
increased with the mutant enzymes (Table 7).
  
 
 
Figure 35. Glycogen titration of Gsy2p.  
The specific activity of wild-type (white circle), W118/W149/H156A3 (black diamond) and D450/R460/F465A3 (grey 
hexagon) enzymes were measured in the absence (a) and presence (b) of saturating 7.2 mM glucose-6-phosphate and 
varying concentrations of glycogen between 0.03 – 12 mg/ml. The activity measurements were done with 4.4 mM UDP-
glucose. The error bars represent the standard error of mean from three independent experiments. 
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Table 7. Specific activity and kinetic parameters of Gsy2p 
 
Enzyme 
Specific activity 
(mmol. min-1) 
V max 
(Glycogen Varied) 
S 0.5 Glycogen 
No G6P 7.2mM G6P No G6P 7.2mM G6P No G6P 7.2mM G6P 
Wild Type  
1.03 ± 0.03 
 
1.73 ± 0.03 
 
1.10 ± 0.01 
 
1.72 ± 0.01 
 
0.25 ± 0.01 
 
0.11 ± 0.01 
118/149/156A3 0.18 ± 0.01 0.56 ± 0.04 0.18 ± 0.02 1.31 ± 0.03 1.72 ± 0.32 4.58 ± 0.25 
450/460/465A3 0.14 ± 0.01 0.49 ± 0.01 0.20 ± 0.02 1.11 ± 0.03 2.72 ± 0.77 5.65 ± 0.06 
118/149/156/ 
450/460/465A6 
0.03 ± 0.00 0.03 ± 0.00 ND ND ND ND 
 
ND – Not Determined 
Specific activity was measured in the presence of 6.7mg/ml of glycogen and 4.4 mM UDP-glucose in the absence and 
presence of 7.2 mM glucose-6-phosphate. Glycogen titration was performed under the same conditions of UDP-glucose 
and glucose-6-phosphate with nine different concentrations of glycogen in the range of 0.03 to 12.0 mg/ml. The errors 
indicate the S.E.M. from three independent experiments 
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I. Insight into inhibition by phosphorylation  
1. Sulfate as phosphomimetic in R580A/R581A/R583A structure 
There are four sulfate ions bound to each of the four monomers in the 
native1 R580A/R581A/R583A structure. Within each monomer, sulfate-1 is 
bound at the position equivalent to that of the distal phosphate of the UDP 
molecule and interacts with the side chains of Arg 320 and Lys 326, as well as 
the main chain atoms of residues Gly 512 and Tyr 513. Sulfate-2 is bound near 
the upper edge of the interdomain cleft towards the N-terminal domain and 
interacts with Arg 20, Lys 29 and Lys 275. Arg 20 also interacts with the sulfate-3 
that is positioned at the dimer interface and interacts with residues Arg 427 and 
Arg 428 from the helix α16 of the other monomer. The fourth sulfate ion is bound 
closer to the tetrameric interface and interacts with residues Gln 582, Asn 585 
and Arg 589 from the regulatory helix (α22).  
As mentioned earlier, the triple mutant crystallizes in two different crystal 
forms and the major difference between the two native apo-enzyme structures is 
in the position of sulfate-4. In the native2 structure, subunits C and D retain the 
sulfate-4 while in the A and B subunits sulfate-4 is absent and is apparently 
replaced by the binding of a single sulfate between the two regulatory helices. 
Residues Arg 589 and Arg 592 are contributed from both the A and B monomers 
to hold the sulfate at the molecular 2-fold axes that runs between and 
perpendicular to the regulatory helices. The molecular consequence of this 
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sulfate binding and apparent displacement of sulfate-4 from the A and B 
subunits, is that the relative positioning of these two monomers within the 
tetramer changes as they are drawn toward one another to better interact with 
the sulfate ion. In the native1 structure, the distance between the main-chain 
atoms of the regulatory helices across the tetrameric interface is approximately 
8.0 Å. Upon binding of the sulfate ion between these helices, their separation 
decreases to 5.1 Å and the N-terminal Rossmann domain of one of the subunits 
(chain B) rotates by an angle of 1.5° towards the intra domain cleft.  
 
 
Figure 366. Sulfate binding at tetramer interface.  
Comparison of sulfate binding at dimer-dimer interface of native-1(a) and native-
2(b) structures. Ribbon diagram of the protein highlighting the interface with the 
bound sulfate represented in space filling models. The residues involved in 
binding are labeled. 
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2. Effect of sulfate on Gsy2p activity 
To determine the effect of sulfate on the enzyme activity, we performed a 
sulfate titration of the yeast Gsy2p wildtype and arginine mutants under the 
standard assay conditions in the presence of 0-1M Li2SO4 (Figure 37).  
The wild type enzyme shows an increase in the activity with Li2SO4 up to 
about 10 mM, whereupon further increase in the sulfate concentration has an 
inhibitory effect on the enzyme activity. Both the triple arginine mutant forms of 
yeast Gsy2p are also inhibited by sulfate, but with different concentration 
dependencies and are not inhibited to the same extent as the wild-type enzyme. 
The inflection points of the curve for the wild type and the R580A/R581A/R583A 
mutant occur at 200 mM sulfate, which is equivalent to the Li2SO4 concentration 
present in our crystallization conditions. It is worth noting that the inhibition curve 
is displaced to the right for the R587A/R589A/R592A mutant that lacks the two 
arginine residues involved in the binding of sulfate between the two regulatory 
helices. In the presence of saturating concentrations of glucose-6-phosphate, the 
arginine mutants show the same effects as that observed in the absence of 
glucose-6-phosphate. However with the wild type enzyme the initial increase in 
activity is not observed and there is a rightward displacement of the inhibition 
curve.  
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Figure 377. Effect of sulfate on Gsy2p activity.  
The specific activity of wildtype (diamond), R580A/R581A/R583A (square) and 
R586/588/592A3 (open triangle) enzymes were measured in the absence (a) and 
presence (b) of saturating 7.2 mM glucose-6-phosphate and varying 
concentrations of Li2SO4 between 0-1M. The activity measurements were done 
with 4.4 mM UDP-glucose and 6.7 mg/ml glycogen. The concentration of sulfate 
used for crystallization is marked shown as red lines. The error bars represent 
the standard error of mean from three individual experiments. 
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DISCUSSION 
A. Overall structure and oligomeric state 
The basic folded architecture of each subunit in Gsy2p and the GT5 family 
members is conserved and includes two Rossmann domains (Figure 35). Within 
the N-domain, the GT3 and GT5 members have two major sequence insertions; 
the position of the insertions in relation to the structural elements of the core 
Rossmann domain is the same but both the lengths and relative three-
dimensional positions vary. Between the β2 and β5 strands, the bacterial 
enzymes have a 35 amino acid insertion whereas in the yeast enzyme the insert 
is longer at about 60 amino acids. The second insert between the β7 strand and 
α10 helix has three helical segments that are positioned between the two 
Rossmann-domains, interacting closely with the C-terminal domain in the yeast 
Gsy2p. In the bacterial enzymes, this same insert is comprised of a two small 
helical segments located on the surface of the N-terminal domain.   
The C-terminal domain of the yeast enzyme also has two unique 
sequence insertions and these insertions are present in all the mammalian 
enzymes. A 100 amino acid insertion is present between the second helix and 
second-strand of the canonical Rossmann-fold. The sequence identity of this 
insert across the different eukaryotic species is between 50-60%. Amongst the 
mammalian enzymes, the sequence identity in this region is even higher, at 
about 90%. A second small insert is present near residue 480 of Gsy2p and is 
also conserved across the eukaryotic species. The long inserts within the N- and 
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C- domains play essential roles for subunit oligomerization whereas the small C-
domain insert is involved in nucleotide sugar donor binding. 
 
Figure 38. Comparison of GT3 and GT5 monomer.  
Ribbon representation of the structure of GS monomer from yeast (a) and E.coli 
(b). The conserved secondary structural elements of the core Rossmann 
domains are represented in purple and cyan, the linker region in yellow and the 
unique eukaryotic inserts in blue and green. 
 
B. UDP binding   
In Gsy2p, the C-domain insertion that begins near residue 480 in Gsy2p 
creates an extended loop that redirects the main chain away from the active site 
region, shortens the following helix (α18) and provides sufficient space to 
facilitate the binding of the uridine ring within and beneath this loop structure 
(Figures 31 and 36).  Repositioning of the helix and the preceding loop enables 
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the side chains of Phe 480 and Tyr 491 to form aromatic stacking interactions 
with the uridine ring.  
 
 
 
Figure 39. Nucleotide binding site in GS.  
Ribbon representation of the superposed Gsy2p (dark grey) and Agrobacterium 
GS (light grey) structures. Gsy2p insert is highlighted in dark pink. The bound 
UDP and ADP are represented in ball and stick models in cyan and green 
respectively.  
 
 
These aromatic side chains are conserved amongst eukaryotic GS 
enzymes. Remarkably, it appears that selectivity for the uridine base is achieved 
by the main chain of Lys 481, which is positioned to donate a single hydrogen 
bond to the exocyclic carbonyl group of the uridine ring (Figure 33). A similar 
interaction is not possible with CDP-sugars nor is the available space sufficient 
for any of the purine-based nucleotide sugars. The pyrophosphate group of the 
UDP interacts with the side chains of Arg 320 and Lys 326, residues that are 
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conserved in all the glycogen synthase enzymes. In addition to these side 
chains, the pyrophosphates of UDP also interact with the helical dipole provided 
by helix α19 and participate in hydrogen bonding interactions with the side chain 
of Thr 514. In the apo and maltodextran bound R580A/R581A/R583A structures, 
a sulfate ion is bound at the position of the UDP β-phosphate group. 
  
 
Figure 40. Sequence alignment of GS. 
Residues represented in red show >90% conservation across various species. The C-domain long helix and 480 loop 
insertions are highlighted in yellow and cyan. Residues involved in maltodextran binding, stabilizing the activated 
conformation are highlighted in green and grey. The regulatory helix is marked by the blue rectangle. 
GYS2_YEAST : --MSR------------------DLQNHLLFETATEV--ANRVGGIYSVLKSKAPITVAQ--YKDHYHLIGPLNKATYQNEVDILDWKKPEAFSDEMRPVQHALQTMESRGVHFVYGRWLIEGAPKVILFDLDSV : 111 
GYS2_DANRE : MRLSRSLSITSLSGLPLFEEESLPVEDLLLFEVAWEV--TNKVGGIYTVIQTKAKITVDE--WGENYFMMGPYYEHNFKTQVEKCEPPNQ--------AIRAAMDSLINNGCQVHFGRWLIEGSPYVILFDIGAA : 123 
GYS2_HUMAN : MLRGRSLSVTSLGGLPQWEVEELPVEELLLFEVAWEV--TNKVGGIYTVIQTKAKTTADE--WGENYFLIGPYFEHNMKTQVEQCEPVND--------AVRRAVDAMNKHGCQVHFGRWLIEGSPYVVLFDIGYS : 123 
GYS1_HUMAN : MPLNRTLSMSSLPGLEDWEDE-FDLENAVLFEVAWEV--ANKVGGIYTVLQTKAKVTGDE--WGDNYFLVGPYTEQGVRTQVELLEAPTP--------ALKRTLDSMNSKGCKVYFGRWLIEGGPLVVLLDVGAS : 122 
GYS1_RABIT : MPLSRTLSVSSLPGLEDWEDE-FDLENSVLFEVAWEV--ANKVGGIYTVLQTKAKVTGDE--WGDNYFLVGPYTEQGVRTQVELLEPPTP--------ALKRTLDSMNSKGCKVYFGRWLIEGGPLVVLLDVGAS : 122 
GYS1_YEAST : --MAR------------------DLQNHLLFEVATEV--TNRVGGIYSVLKSKAPVTVAQ--YGDNYTLLGPLNKATYESEVEKLDWEDESIFPEELLPIQKTLMSMREKGVNFVYGNWLIEGAPRVILFELDSV : 111 
GYS_ATU    : ---------------------------MNVLSVSSEIYPLIKTGGLADVVGALPIALEAHGVR---TRTLIPGYPAVKAAV--TDPVKCFEFTDLLGE------------KADLLEVQHE---RLDLLILDAPAY :  88 
                                                                                                                                                           
GYS2_YEAST : -RGYSNEWKGDLWSLVGIPSPENDFETNDAILLGYTVAWFLGEVA-HLDSQHAIVAHFHEWLAGVALPLCRKR-RIDVVTIFTTHATLLGRYLCASGSFDFYNCLESVDVDHEAGRFGIYHRYCIERAAAHSADV : 243 
GYS2_DANRE : -AWNLDRWKGDLWSACGIGLPYHDREANDSLILGSLVAWFFKELTDQLQDKLNVVAHFHEWQAGTGLVLSRSR-NLPLATIFTTHATLLGRYLCAG-NADFYNNLDKFDIDREAGERQIYHRYCLERAAVHCAHV : 255 
GYS2_HUMAN : -AWNLDRWKGDLWEACSVGIPYHDREANDMLIFGSLTAWFLKEVTDHADGKY-VVAQFHEWQAGIGLILSRAR-KLPIATIFTTHATLLGRYLCAA-NIDFYNHLDKFNIDKEAGERQIYHRYCMERASVHCAHV : 254 
GYS1_HUMAN : -AWALERWKGELWDTCNIGVPWYDREANDAVLFGFLTTWFLGEFLAQSEEKPHVVAHFHEWLAGVGLCLCRAR-RLPVATIFTTHATLLGRYLCAG-AVDFYNNLENFNVDKEAGERQIYHRYCMERAAAHCAHV : 254 
GYS1_RABIT : -AWALERWKGELWDTCNIGVPWYDREANDAVLFGFLTTWFLGEFLAQNEEKPHVVAHFHEWLAGIGLCLCRAR-RLPVATIFTTHATLLGRYLCAG-AVDFYNNLENFNVDKEAGERQIYHRYCMERAAAHCAHV : 254 
GYS1_YEAST : -RHFLNEWKADLWSLVGIPSPEHDHETNDAILLGYVVVWFLGEVS-KLDSSHAIIGHFHEWLAGVALPLCRKK-RIDVVTIFTTHATLLGRYLCAAGDVDFYNNLQYFDVDQEAGKRGIYHRYCIERAAAHTADV : 243 
GYS_ATU    : -YER---SGGP---YLGQTGKDYPDNWKRFAALSLAAARIGA---GVLPGWRPDMVHAHDWQAAMTPVYMRYAETPEIPSLLTIHNIAFQGQFGANIFSK----LALPAHAFGMEGIEYYNDVSFLKGGLQTATA : 209 
 
GYS2_YEAST : FTTVSQITAFEAEHL-----------LKRKPDGILPNGLNVIKFQAF----------HEFQNLHALKKEKINDFVRGHFHGCFDFDLDNTLYFFIAGRYEYKNKGADMFIEALARLNYRLKVSGSKKTVVAFIVM : 357 
GYS2_DANRE : FTTVSQITAVEADHM-----------LHRNPDVVTPNGLNVRKFSAM----------HEFQNLHSMNKSKIQEFVRGHFYGHLDFNLEKTLFFFIAGRYEFSNKGADLFLESLSRLNYLLRVHKSDVTVVVFFIM : 369 
GYS2_HUMAN : FTTVSEITAIEAEHM-----------LKRKPDVVTPNGLNVKKFSAV----------HEFQNLHAMYKARIQDFVRGHFYGHLDFDLEKTLFLFIAGRYEFSNKGADIFLESLSRLNFLLRMHKSDITVVVFFIM : 368 
GYS1_HUMAN : FTTVSQITAIEAQHL-----------LKRKPDIVTPNGLNVKKFSAM----------HEFQNLHAQSKARIQEFVRGHFYGHLDFNLDKTLYFFIAGRYEFSNKGADVFLEALARLNYLLRVNGSEQTVVAFFIM : 368 
GYS1_RABIT : FTTVSQITAIEAQHL-----------LKRKPDIVTPNGLNVKKFSAM----------HEFQNLHAQSKARIQEFVRGHFYGHLDFNLDKTLYFFIAGRYEFSNKGADVFLEALARLNYLLRVNGSEQTVVAFFIM : 368 
GYS1_YEAST : FTTVSQITALEAEHL-----------LKRKPDGILPNGLNVVKFQAV----------HEFQNLHALKKDKINDFVRGHFHGCFDFDLDNTVYFFIAGRYEYKNKGADMFIESLARLNYRLKVSGSKKTVVAFLIM : 357 
GYS_ATU    : LSTVSPSYAEEILTAEFGMGLEGVIGSRAHVLHGIVNGIDADVWNPATDHLIHDNYSAANLKNRALNKKAVAEHFRI--------DDDGSPLFCVIS-RLTWQKGIDLMAEAVDEIVSL-------GGRLVVLGA : 328 
 
GYS2_YEAST : PAKNNSFTVEALKGQAEVRALENTVHEVTTSIGKRIFDHAIRYPHNGLTTELPTDLGELLKSSDKVMLKRRILALRRPEGQLPPIVTHNMVDDANDLILNKIRQVQLFNSPSDRVKMIFHPEFLNANNPILGLDY : 492 
GYS2_DANRE : PAKTNNFNVESLKGQAVRKQLWDTAQSVKEKFGKKLYESLLRG-------EIP-DMSKILDRDDFTIMKRAIYATQRH--SLPPVTTHNMLDDSTDPILGNIRRIGLFNGRNDRVKIVFHPEFLSSTSPLLPMDY : 494 
GYS2_HUMAN : PAKTNNFNVETLKGQAVRKQLWDVAHSVKEKFGKKLYDALLRG-------EIP-DLNDILDRDDLTIMKRAIFSTQRQ--SLPPVTTHNMIDDSTDPILSTIRRIGLFNNRTDRVKVILHPEFLSSTSPLLPMDY : 493 
GYS1_HUMAN : PARTNNFNVETLKGQAVRKQLWDTANTVKEKFGRKLYESLLVG-------SLP-DMNKMLDKEDFTMMKRAIFATQRQ--SFPPVCTHNMLDDSSDPILTTIRRIGLFNSSADRVKVIFHPEFLSSTSPLLPVDY : 493 
GYS1_RABIT : PARTNNFNVETLKGQAVRKQLWDTANTVKEKFGRKLYESLLVG-------SLP-DMNKMLDKEDFTMMKRAIFATQRQ--SFPPVCTHNMLDDSSDPILTTIRRIGLFNSSADRVKVIFHPEFLSSTSPLLPVDY : 493 
GYS1_YEAST : PAKTNSFTVEALKSQAIVKSLENTVNEVTASIGKRIFEHTMRYPHNGLESELPTNLDELLKSSEKVLLKKRVLALRRPYGELPPVVTHNMCDDANDPILNQIRHVRLFNDSSDRVKVIFHPEFLNANNPILGLDY : 492 
GYS_ATU    : GD---------------------------------------------------------------------------------------------VALEGALLAAASRHHG--RVGVAIGYNE---------PLS : 359 
 
GYS2_YEAST : DEFVRGCHLGVFPSYYEPWGYTPAECTVMGVPSITTNVSGFGAYMEDLIETNQAK--------DYGIYIVDRRFKAPDESVEQLVDYMEEFVKKTRRQRINQRNRTERLSDLLDWKRMGLEYVKARQLALRRGYP : 619 
GYS2_DANRE : EEFVRGCHLGVFPSYYEPWGYTPGECTVMGIPSVTTNLSGFGCFMEEHVSDPSE----------YGIYIVDRRFRSADESCNQLTQFMFSFCQKSRRQRIIQRNRTERLSDLLDWRYLGRFYMHARHLALSRSFP : 619 
GYS2_HUMAN : EEFVRGCHLGVFPSYYEPWGYTPAECTVMGIPSVTTNLSGFGCFMQEHVADPTA----------YGIYIVDRRFRSPDDSCNQLTKFLYGFCKQSRRQRIIQRNRTERLSDLLDWRYLGRYYQHARHLTLSRAFP : 618 
GYS1_HUMAN : EEFVRGCHLGVFPSYYEPWGYTPAECTVMGIPSISTNLSGFGCFMEEHIADPSA----------YGIYILDRRFRSLDDSCSQLTSFLYSFCQQSRRQRIIQRNRTERLSDLLDWKYLGRYYMSARHMALSKAFP : 618 
GYS1_RABIT : EEFVRGCHLGVFPSYYEPWGYTPAECTVMGIPSISTNLSGFGCFMEEHIADPSA----------YGIYILDRRFRSLDDSCSQLTSFLYSFCQQSRRQRIIQRNRTERLSDLLDWKYLGRYYMSARHMALAKAFP : 618 
GYS1_YEAST : DEFVRGCHLGVFPSYYEPWGYTPAECTVMGVPSITTNVSGFGAYMEDLIETDQAK--------DYGIYIVDRRFKSPDESVEQLADYMEEFVNKTRRQRINQRNRTERLSDLLDWKRMGLEYVKARQLGLRRAYP : 619 
GYS_ATU    : HLMQAGCDAIIIPSRFEPCGLTQLYALRYGCIPVVARTGGLADTVI----DANHAALASKAAT--GVQFSP----VTLDGLKQAIRRTVRYYHD--PKLWTQMQKLGMKSDVS-WEKSAGLYA-ALYSQLISKGH : 480 
 
GYS2_YEAST : DQFRELVGEELNDSNMDALAGGKK-LKVARPLSVPGSPRDLRSNSTVYMTPGDLGTLQEVN-----------NADDY----------FSLGVN----------------------PAADDDDD----GPYADDS- : 705 
GYS2_DANRE : EKFRPEH-------LNLTSTQG---FRYPRPSSVPPSPSASIH-----STPHHSDEEDDDTYDEEEEAERDRLNIKAP---------FSVGADTDGKRTQPVENGN----------------------------- : 701 
GYS2_HUMAN : DKFH----------VELTSPPTTEGFKYPRPSSVPPSPSGSQA-----SSPQSSDVEDEVE------DERYDEEEEAERDRLNIKSPFSLSHVPHGKKKLHGEYKN----------------------------- : 703 
GYS1_HUMAN : EHFT----------YEPNEADAAQGYRYPRPASVPPSPSLSRH-----SSPHQSEDEEDPRNGPLEEDGERYDEDEEAAKDRRNIRAPEWPRRASCTSSTSGSKRNSVDTATSSSLSTPSEPLSPTSSLGEERN- : 737 
GYS1_RABIT : DHFT----------YEPHEADATQGYRYPRPASVPPSPSLSRH-----SSPHQSEDEEEPRDGLPEEDGERYDEDEEAAKDRRNIRAPEWPRRASCTSSSGGSKRSNSVDT--SSLSTPSEPLSPASSLGEERN- : 735 
GYS1_YEAST : EQFKQLVGETISDANMNTLAGGKK-FKIARPLSVPGSPK-VRSNSTVYMTPGDLGTLQDAN-----------NADDY----------FNLSTN----------------------GAIDNDDDDNDTSAYYEDN- : 708 
GYS_ATU    : --------------------------------------------------------------------------------------------------------------------------------------- :   - 
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C. Catalytic mechanism 
GS enzymes are metal ion independent retaining type glycosyl 
transferases whose mechanism of action remains elusive. One study with the 
human muscle GS enzyme suggested a SN2 type reaction with the two glutamate 
residues of the conserved E-X7-E motif acting as the nucleophile and general 
acid/base38. In our structures, the proposed nucleophile, Glu 509 of the Gsy2p is 
turned away from the active site and interacts with the side chain of Lys 326, 
which might be a preferred mode of interaction in the absence of a donor sugar 
attached to the nucleotide. Rather than acting as a nucleophile, Glu 509 might be 
involved in stabilizing the pyrophosphate of the leaving group by correctly 
positioning the charged residues Arg 320 and Lys 326. Alternatively, a different 
residue, such as Tyr 513, might function as the nucleophile in the eukaryotic 
organisms. The second glutamate residue in the E-X7-E motif - Glu 517 - is 
conserved only in the eukaryotic and archaeal enzymes that are capable of using 
UDP-glucose as the substrate. In our UDP bound structure, Glu 517 is positioned 
to interact with the 2’ and 3’ hydroxyls of the uridine ribose moiety and is, 
therefore, unlikely to act as the general acid/base for the catalytic reaction.  
However, an unusual cluster of polar residues comprised of His 166, His 168, Thr 
191, His193 and Thr 245 form a hydrophilic core within the N-terminal domain 
and appear to link the active site region with solvent. These residues are 
conserved across all the GS enzymes. We speculate that His193 might be the 
general base and that the remaining residues could serve as a proton wire 
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shuttling protons from the active site to solvent without the need to reset the 
protonation state of the active site through release and rebinding of the growing 
acceptor molecule. A possible role for high efficiency proton shuttling would be to 
provide a mechanism through which the processivity of eukaryotic GS enzymes 
is enhanced. Consistent with this proposal, mutation of the central residue in this 
hydrogen bonding network, His 166, reduces catalytic activity to 1% of wild-
type62.  
D. Maltodextran binding sites 
Binding of maltodextran to the same two sites in subunits A and B of the 
R580A/R581A/R583A mutant was observed both in soaking and co-
crystallization experiments with maltooctaose. The two sites are found on the 
surface of the N-terminal (site 1) and C-terminal (site 2) Rossmann-fold domains 
(Figure 37c). The hydrophobic and the polar residues that constitute these 
maltodextran binding sites are highly conserved across the eukaryotic species 
(Figure 40). It is interesting to note that maltodextran binding sites equivalent to 
our site 1 position are also found in glycogen phosphorylase (termed the 
glycogen storage site) and in the E.coli glycogen synthase enzymes (Figure 37). 
In each case, the locations are approximately similar, but the maltodextran 
binding sites share no sequence or structural homology and are formed from 
unique elements of secondary structure. The site 1 region on the C and D 
subunits are utilized in crystal packing contacts and are unavailable to interact 
with maltodextran in the low activity state structure.   
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The second maltodextran binding site is located in the C-terminal domain 
and appears to be unique to the eukaryotic enzymes. Like the site 1 binding cleft, 
this site is also lined with conserved residues and is located at the structural 
boundary between the long helices that form the oligomeric interface and the C-
terminal Rossmann domain. Interestingly, three missense mutations reported in 
the human liver GS enzyme that lead to glycogen storage disease type-0 occur 
amongst conserved residues that are located in close proximity to this second 
maltodextran binding site. 
 
Figure 40. Maltodextran binding sites in GTB enzymes.  
Ribbon representation of themonomer structure of rabbit muscle glycogen 
phosphrylase (a), E.coli GS (b) and yeast Gsy2p (c). The bound maltodextran 
polymers are represenced in space fill models.  
 
In Gsy2p, the 4’ ends of the polymers bound at each site are between 30 
and 35 Å from the catalytic site (Figure 41c) and as such do not appear to 
represent sites appropriate for proper positioning of the acceptor end of the 
growing glycogen chain. Instead, consistent with the multiple polymer binding site 
model for rabbit GYS144, we propose that these are non-catalytic, docking sites 
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for glycogen on the synthase enzyme, which either keeps the enzyme in close 
proximity to the polymer for efficient catalysis or provides a convenient docking 
site while the branching enzyme acts on chains that have reached lengths 
appropriate for introduction of a branch point. The multiple binding sites may 
explain the propensity of glycogen synthase to remain tightly associated with the 
glycogen particle and may suggest a role for increasing the processivity of 
glycogen synthase. The maltodextran binding site mutants support this model as 
the mutation of critical residues in these sites decreases the Vmax and the S0.5 
glycogen of the enzyme. In the presence of glucose-6-phosphate, the S0.5 
glycogen is decreased by half for the wild type enzyme whereas it is increased 
two to three times for the mutants (Table 7). Since there are no changes in the 
catalytic and allosteric sites of the wild type and mutant Gsy2p, the allosteric 
effects of glucose-6-phosphate should be similar. The higher activity of the 
enzyme in the presence of glucose-6-phosphate demands the need for greater 
amount of the polymer substrate for extension. Since the wild type enzyme is 
tightly associated with glycogen, there is always excess glycogen available. 
However, the mutants are not tightly bound with glycogen and hence we need an 
increased local concentration of the substrate to fulfill the demands of the 
activated enzyme, which is reflected in the increase in the S0.5 glycogen. 
D. Activation by glucose-6-phosphate 
The 100 amino acid C-domain insertion of Gsy2p fold as an extended 
coiled-coil, traverses the dimer-dimer interface and forms two four-helical 
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bundles comprising the majority of interactions in the oligomer assembly. The 
helix α-16 of the coiled-coil domain interacts with helix α2 and strand β3 within 
each N-domain insertion in the low activity state - R580A/R581A/R583A 
structures (Figures 25 and 30a). This interaction between the N-terminal and C-
terminal insertions represents the primary points of contact between the large 
oligomerization insertion and the remainder of the enzyme in these structures. 
This assembly positions the regulatory helices far away from each other in the 
dimer (~60 Å). However, when the two dimers are assembled back-to-back in the 
tetramer, these same regulatory helices are now positioned opposite their partner 
helices at a distance of approximately 8 Å in the R580A/R581A/R583A structures 
(Figure 26). The interactions of α-16 helix with the N-terminal insertion are 
replaced by interactions with residues 482-487 when the helical domains 
collapse toward the central interface in response to glucose-6-phosphate binding 
(Figure 30b).   
As might be expected for an allosteric molecule that induces such large 
conformational changes, the interactions between the enzyme and glucose-6-
phosphate are extensive and involve residues from more than one subunit 
(Figure 28). In particular, the 6-phosphate is completely enclosed in a binding 
pocket comprised of five residues (His 286, Lys 290, His 500, Arg 583 and Arg 
587) that are conserved across eukaryotes. The C1’ and C2’ hydroxyl groups of 
the glucose moiety forms hydrogen bonds to Gln 283 and His 280, respectively.  
Unlike the majority of the phosphate-binding site, the glucose binding site is not 
well-formed prior to binding. In particular, residues 278 to 284 are disordered in 
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the basal state and adopt a stable conformation only when the activator is bound 
(Figure 29). Consequently, most of the conformational changes are brought 
about by the interactions surrounding the glucose moiety, including those 
contributed by the opposing subunit. The phosphoryl group serves as a strong 
anchor upon which to build the necessary interactions to drive the conformational 
changes. 
Based on the changes in local structure, it would appear that the trigger 
for these conformational changes are the interactions contributed by His 280, Gln 
283 and Asn 284, the latter of which hydrogen-bonds with itself across the 
subunit interface. Although residues His 286 and Lys 290 also contribute 
hydrogen bonds to the bound glucose-6-phosphate, their relative positions 
change very little upon glucose-6-phosphate binding. Rather the ordering of the 
loop between 278 and 284 and drawing of this loop into interactions across the 
regulatory interface stabilizes the activated conformation by pushing the helices 
apart and inducing rigid body rotations and translations in order to achieve 
optimal interactions for His 280, Gln 283 and Asn 284. The only other residue 
that may assist in stabilizing this new interface is the side-chain of Arg 581, which 
forms weak and variable interactions with the main-chain carbonyl oxygen atoms 
of residues 276 and 277 in the opposing subunit. However, given its 
comparatively weak electron density and the mutagenesis data on Arg 581 
(Table 6), this residue is likely more important in determining the structural 
response to phosphorylation than in contributing to the stability of the activated 
conformation. 
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The reorganization of the subunit interface likely leads to increased 
enzymatic activity because the active site clefts are now freely open for substrate 
access and the N-terminal Rossmann domains at the periphery of the tetramer 
are no longer anchored by their interactions with helix α16 (Figure 40). Structural 
studies with glycogen synthase from E.coli have demonstrated that the transition 
between the resting open and catalytically-poised closed conformation of the 
enzyme involves a 15° inter-domain rotation72. The relative domain orientation of 
Gsy2p in the low activity state is most similar to the open-form of the E.coli 
enzyme and domain closure similar to the E.coli enzyme is hindered by the 
interactions between the N-terminal domains and helix α16. However, upon 
activator binding, the resulting changes in subunit positioning frees the N-
terminal domains from the constraining interactions with α16 and the enzyme can 
adopt the opened and closed domain conformations required for catalysis 
(Figures 40 and 41). Consistent with this hypothesis, the N-terminal domains of 
the A, C and D subunits are actually rotated an additional 4.6° away from the 
interface in the activated structure than in the R580A/R581A/R583A structure 
(Figure 42).  Interestingly, the B subunit is 12.8° more closed than in the basal 
state structure.  This domain closure appears to be precipitated by serendipitous 
binding of an additional glucose-6-phosphate molecule within the active site that 
triggers the domain closure. No such variation in domain orientation was 
observed in the low activity structure, which is consistent with our contention that 
the subunit positioning in the activated state facilitates catalytically important 
conformational changes. 
  
 
 
Figure 41. Comparison of Gsy2p conformations – Active site.  
(a) Ribbon representation of Gsy2p low activity state(R580A/R581A/R583A tetramer) structure with the bound sulfates in 
space filling models. (b) Ribbon representation of Gsy2p activated conformation (R589A/R592A tetramer) with the bound 
glucose-6-phosphate in space filling models Different colors are used to represent different subunits. 
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Figure 42. Comparison of Gsy2p conformations - Regulatory helix interface.  
(a) Ribbon representation of Gsy2p low activity state(R580A/R581A/R583A tetramer) structure with the bound sulfates in 
space filling models. (b) Ribbon representation of Gsy2p activated conformation (R589A/R592A tetramer) with the bound 
glucose-6-phosphate in space filling models Different colors are used to represent different subunits. 
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Figure 43. Comparison of the R580A/R581A/R583A and R589A/R592A 
activated state conformations.  
Ribbon representation of the superposed basal state and activated state subunit 
A (a) and subunit B (b) with the bound glucose-6-phosphate in space filling 
model. Different colors represent different conformations: orange-low activity, 
blue-high activity. The alignment was generated by superposing the C-terminal 
Rossmann domain (residues 312-357 and 453-577) using the superpose 
program of the CCP4 suite. 
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E. Role of Regulatory helix arginines in conformational transition 
The mutagenesis and intein-mediated phospho-peptide ligation data 
suggest the arginine residues within the regulatory helix play specific roles in the 
conformational selection process that ultimately control the different activity 
states. First, it is clear from the double mutants and the glucose-6-phosphate 
activated structure that Arg 583 and Arg 587 are necessary and sufficient for 
conferring glucose-6-phosphate sensitivity. But rather than directly triggering the 
conformational changes upon activator binding, their roles are to provide 
anchoring interactions for the phosphate so that the interactions conferred by 
residues 280-284 with the glucose moiety can trigger the conformational 
changes. Second, in the absence of glucose-6-phosphate, charge neutralization 
of the other four arginines is in some way responsible for shifting the equilibrium 
from an activated state toward a less active state. 
The mutagenesis data show that neither Arg 580 nor Arg 581 make 
significant contributions toward establishing the basal activity state or toward 
stabilizing the glucose-6-phosphate activated state (Table 6). However, prior 
work62 and the current intein-mediated phospho-peptide data demonstrate that 
their contributions are critical to stabilize the inhibited state following C-terminal 
phosphorylation. Therefore, these two arginine residues likely contribute to the 
binding of the phosphorylated Thr 668 residue and/or help hold the enzyme in a 
less active state. On the other hand, Arg 589 and Arg 592 seem critical to 
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establishing the activity of the basal state, since their mutation to alanine reduces 
the basal activity of the enzyme to levels similar to the phosphorylated state.   
F. Inhibition by C-terminal phosphorylation 
  The kinetic studies demonstrate that sulfate concentrations similar to that 
utilized in the crystallization of the R580A/R581A/R583A mutant has an inhibitory 
effect on the enzyme activity. The kinetic effects of sulfate are not simply the 
result of non-specific inhibition by high ionic strength since neither of the two 
triple mutants exhibit the moderate activation or full inhibition shown by the wild-
type enzyme in response to varied sulfate concentrations. Thus, the behavior of 
the triple mutants toward sulfate is similar to that toward the physiological 
activators and inhibitors; their response is muted when compared to the wild-type 
enzyme. Since sulfates are known phosphomimics, we suggest that the inhibitory 
phosphates bind at or near the regulatory helices, similar to the sulfate binding 
seen in the low activity state structure and result in charge neutralization of these 
arginine residues. Though the precise location of the phosphate at the regulatory 
helix is not known, we speculate that phosphate binding would result in 
constraining the positions of the regulatory helices and limit the conformations 
accessible to the inhibited state. It is possible that the low specific activity, the 
increase in the KM for UDP-glucose and the changes in M0.5 for glucose-6- 
phosphate exhibited by the phosphorylated state of Gsy2p are indirect effects of 
these conformational restraints. 
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 Either an intra- or intersubunit interaction with the phosphothreonine 
residue at position 668 would fulfill the requirement for charge neutralization of 
the regulatory arginines. However, an intersubunit interaction would add an 
additional conformational constraint in the form of a locking strap running from 
the N-terminal domain of the opposing subunit, where the electron density of the 
low activity structure terminates at residue 640 approximately 25-30 Å from the 
regulatory interface, across the interface to the regulatory helix located on the 
opposing C-terminal domain (Figure 42). Indeed, the additional residues 
observed at the C-terminus of the glucose-6-phosphate activated structure of the 
R589A/R592A mutant are directed precisely toward the regulatory interface 
(Figure 42). The basal activity of the R589A/R592A double mutant support an 
intermolecular locking mechanism as its lower activity ratio does not approach 
the activity ratio of the phosphorylated wild-type enzyme and an intermolecular 
mechanism is also supported by the stronger inhibition of the longer 
phosphopeptide construct (Table 6). Binding of glucose-6-phosphate presumably 
disrupts these locking interactions through the conformational changes across 
the regulatory interface and throughout the tetramer.  
 While phosphorylation of the Thr668 residue alone decreases the activity 
ratio of Gsy2p in a manner comparable to that of the in vitro phosphorylated 
enzyme, this is not sufficient to completely block the access of the glucose-6- 
phosphate to the activity state. The M0.5 of glucose-6-phosphate for the in-vitro 
phosphorylated form of Gsy2p is 800 µM, which is 20 times greater than the 
value for the dephosphorylated form62. However, ligation of either the 35-mer or 
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the 49-mer Thr668 phosphopeptide to the wild type Gsy2p core only increased 
the M0.5 by three-fold . This suggests that additional phosphates at the serine 
residues are necessary for blocking the access of the activator to the allosteric 
site and one possibility is that one of the inhibitory phosphates could interact with 
the 6-phosphate binding site of the activator.  
 G. Regulatory model for Gsy2p 
Based on the current structural and biochemical work on Gsy2p, we 
provide molecular insight into the nature of the three activity states of Gsy2p, 
which span a 20-fold range of specific activity and the apparent driving forces 
that shift the conformational equilibrium between these states (Figure 44). Rather 
than three distinct states, we believe that there is a dynamic equilibrium between 
the three states and the specific activity is an indication of the conformational 
flexibility available for a particular enzyme to exist in each state. This raises the 
probability of some intermediate conformation and indeed the 
R580A/R581A/R583A structures are examples of such intermediate 
conformation between the basal activity intermediate state and the low activity 
inhibited state.   
In the highest activity (R) state, binding of glucose-6-phosphate adjacent 
to the regulatory helices pushes the helices apart and results in domain rotations 
and translations that frees the conformational restraints, opens up the active site 
and facilitates interdomain motions that are necessary for catalysis. The 
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activated conformation is stabilized by the ordering of residues 277-284 that not 
only interact with the activator molecule within its own subunit but also with the 
associated monomer.   
 
 
Figure 44. Three state structural model for Gsy2p. 
Three state structural model for regulation of Gsy2p. Different colors are used to 
represent the individual subunits of the tetramer and the dotted lines represent 
the disordered C-terminal region in the intermediate and activated states. 
 
Though we lack solid structural data on the inhibited (T) state 
conformation, based on the kinetic data and the structural information from the 
triple mutant, we propose that binding of phosphate at or near the regulatory 
helix would result in structural collapse of the helices, pull the subunits closer and 
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restrain the domain motion involved in catalysis. While a single phosphate group 
at the Thr 668 position is sufficient to inhibit the enzyme activity, we suggest that 
the additional phosphates and the conserved hydrophobic patch in the C-terminal 
region provide a locking mechanism to stabilize the T state conformation. Based 
on the regulatory helix movement seen in the R580A/R581A/R583A structures, 
we would expect that the dephosphorylated wild-type enzyme to have an 
intermediate level of flexibility.  
Since the secondary structural elements that are involved in 
oligomerization and activity regulation are highly conserved between the 
mammalian GS enzymes and yeast Gsy2p, this work establishes the paradigm 
for regulatory control of the mammalian glycogen synthases. The major 
difference between the mammalian and the yeast enzymes is the presence of 
additional phosphorylation sites in the C and N-terminal regions. As mentioned 
earlier, the additional phosphorylation sites could provide further locking 
interactions to stabilize the inhibited conformation. In all our structures, the N-
terminus is positioned similar to the C-termini at a distance of 40 Å from the 
regulatory helices, but the spatial positioning in the tetramer is such that any N-
terminal extensions would have easy access to the regulatory helices (Figure 
41). Hence it is possible that the N-terminal phosphorylation sites also bind to the 
regulatory helices and restrain the conformations as we predict for the C-terminal 
sites. While the specific activity of the different conformational states of yeast 
Gsy2p vary by approximately 20-fold62, the different activity states of the 
mammalian enzymes show a much higher variation in the specific activity (> 200 
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fold)95,96. It is possible that the complex nature of the mammalian tissues demand 
the presence of additional phosphorylation sites to transmit and integrate signals 
from different inputs for manipulating and fine tuning the GS enzyme activity over 
a large range to meet the physiological requirement of the specific involved  
tissues.  
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CONCLUSIONS 
The structure of yeast Gsy2p in the low activity and glucose-6-phosphate 
bound activated conformations provides the molecular and structural basis of 
regulation of eukaryotic GS enzymes. The most intriguing feature of Gsy2p is the 
tetrameric arrangement mediated by the helical insert in the C-terminal domain; 
this unique arrangement facilitates extensive conformational flexibility and 
effective communication between the active site of the individual subunits, which 
are essential for the regulation of enzymatic activity. The conserved arginines are 
located in a single helix and are positioned at a molecular two-fold of the tetramer 
assembly. The arginines function as sensors for both the activator and the 
inhibitory signals and are involved in fine tuning the enzyme activity in response 
to the physiological demands of the cells or tissues. Binding of glucose-6- 
phosphate at the tetrameric interface adjacent to the regulatory helix relieves the 
conformational restraints imparted on the subunits and thus facilitates the intra 
domain rotations necessary for enzyme activity. Inhibitory phosphate binding at 
or near the regulatory helix would lock the enzyme in a restrained conformation 
and thus impede these movements. A small insert if the C-terminal domain at the 
substrate binding site is involved in mediating the UDP-glucose specificity of the 
eukaryotic enzymes. Further, the presence of sugar polymer acceptor binding 
sites on the enzymes surface help the tight association of the enzyme with the 
substrate and increases the processivity of the enzyme.     
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FUTURE DIRECTIONS 
 
We have collected a 2.5 Å dataset of the UDP and maltodextran bound 
complexes of the activated conformation of Gsy2p and expect that these 
structures would provide additional clues on the mechanism of enzyme activation 
induced by the rotational movements of the domains. The structures of the 
complexes were solved by molecular replacement using the R589A/R592A 
glucose-6-phosphate bound tetramer as the search model. Preliminary analysis 
of the structures showed no significant changes in the UDP binding, but we do 
observe additional maltodextran polymer binding sites in the activated 
conformations.  We have also collected a 2.5 Å dataset of the activated 
conformation of the R580A/R581A mutant in the I222 space group and solved 
the structure using the R589A/R592A tetramer as the search model. Analysis of 
our current model did not show any significant changes in the activated 
conformation.   
Our next structural work will focus on both the state I and state R. We 
have some crystals hits for the apo form of R589A/R592A mutant; optimization of 
the hit and solution of the apo structure would give substantial information on the 
inhibited conformation. A new screen for the apo form of the wild type, 
R580A/R581A and the T667 phosphopeptide ligated wild type has to be 
performed to gain additional information on the intermediate and activated 
conformations. Site-directed mutageneis and enzyme kinetic studies have to be 
done to confirm the role of the conserved polar His cluster in catalysis. The 
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glucose-6-phosphate bound in the active site of the B subunit in the activated 
conformation provides some insights on the catalytic nucleophiles and these 
have to be tested by mutagenesis and enzyme kinetic approaches.  
The ultimate goal of this project is to extend the studies to the mechanism of 
regulation of the mammalian GS enzymes. Since the yeast Gsy2p shares 50% 
sequence identity to the mammalian species and the secondary structural 
elements are conserved between the two species, we would expect to solve the 
mammalian GS structures by molecular replacement using the yeast structure as 
the search model.  
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APPENDICES  
1. SOLVE/RESOLVE script for determining heavy atom position and density 
modification 
setenv   SYMINFO /usr/local/lib/solve/syminfo/lib 
setenv   CCP4_OPEN UNKNOWN 
setenv   SOLVETMPDIR /var/tmp 
setenv   SYMOP /usr/local/lib/solve/symop.lib 
setenv   SYMINFO /usr/local/lib/solve/syminfo.lib 
unlimit 
#output and log file solve an MIR problem 
solve<<EOD  >  solve.log 
logfile   solve.logfile 
#resolution and symmetry  
resolution   20  5.0 
cell  96.5   166.3   121.1   90.0   103.4   90.0 
symfile    /usr/local/lib/solve/p21.sym 
#native data  
readdenzo 
premerged 
read_intensities 
fixscattfactors 
rawnativefile   native1.sca 
#derivative 1 
derivative 1 
label  deriv  1 TA36 
atom  ta 
rawderivfile   tbr36.sca 
nsolsite_deriv   6 
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#derivative 2 
derivative 2 
label  deriv  2 TA44 
atom  ta 
rawderivfile   tbr44.sca 
nsolsite_deriv   5 
SCALE_NATIVE 
SCALE_MIR 
ANALYZE_MIR 
SOLVE 
EOD 
#resolve for density modification 
resolve  << EOD  >  resolve.log 
solvent_content   0.58 
nobuild 
EOD 
 
2. PHENIX script for partial model phasing 
phenix.autobuild Maps_only=True \ 
model=partial_model2.pdb \ 
phenix.simple_ncs_from_pdb partial_model.pdb \ 
data=solve.mtz \ 
input_hires_file=nativet1.mtz \ 
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3. Pymol script for generating figures with difference electron density maps 
around bound ligand 
set bg_rgb,[1.0, 1.0, 1.0] 
set ray_trace_fog, 0 
cmd.space('cmyk') 
set two_sided_lighting,1 
set cartoon_fancy_helices,1 
set ray_shadows, 0 
set stick_radius=0.2 
set stick_ball=on 
set stick_ball_ratio=1.2 
set mesh_radius = 0.025 
load 589a2_g6pa.pdb, g6p 
cmd.dss("g6p") 
load 589a2.pdb, gsy2 
cmd.dss("gsy2") 
set_color grey, (0.7,0.7,0.7) 
select monA, (resi 2-639 and chain A) 
select monB, (resi 2-639 and chain B) 
hide all 
show cartoon, gsy2 
alter 280-301/, ss='H' 
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alter 599-611/, ss='H' 
rebuild 
select surres, (resi 587, resi 583, resi 580, resi 581, resi 500, resi 286, resi 290, 
resi 283, resi 284, resi 280, resi 277, resi 281) 
show stick, g6p 
show stick, surres 
hide ("surres" and name n+c+o) 
util.cba (130,"monA")   
util.cba(70,"g6p") 
util.cba(30,"monB") 
load 589a2_g6pa.ccp4, map1 
isomesh diffmap, map1, 1.0, (g6p), 1, carve=2.1 
set_color cyan=[0.1, 1.0, 1.0] 
color cyan, diffmap 
deselect 
set_view (\ 
    -0.085544080,   -0.994874537,   -0.053918786,\ 
     0.831045389,   -0.101099811,    0.546939194,\ 
    -0.549586892,    0.001979203,    0.835435867,\ 
     0.000000000,    0.000000000,  -79.028060913,\ 
    38.875000000,  -26.892000198,   41.817001343,\ 
    71.476737976,   86.579383850,    0.000000000 ) 
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4. Pymol script for generating figures with ligands and intreracting 
residues represented in space filling models and lines respectively  
set bg_rgb,[1.0, 1.0, 1.0]   
set ray_trace_fog, 0   
cmd.space('cmyk')  
set cartoon_smooth_loops, 1   
set two_sided_lighting,1 
set cartoon_fancy_helices,1 
set ray_shadows, 1  # set 0 for interior shot  
set antialias, 1 
set line_width = 6.0 
load nativet1.pdb, R580final 
cmd.dss("R580final") 
hide all  
select Aso4, (resn SO4 and chain A) 
select Bso4, (resn SO4 and chain B) 
show spheres, Aso4 
util.cba(3,"Aso4") 
show spheres, Bso4 
util.cba(3,"Bso4") 
select monA, (resi 2-639 and chain A) 
color blue, monA 
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show cartoon, monA 
select monB, (resi 2-639 and chain B) 
color orange, monB 
show cartoon, monB 
select argres, ( resi 589, resi 592) 
show lines, argres 
select monC, (resi 2-639 and chain C) 
hide monC 
select monD, (resi 2-639 and chain D) 
hide monD 
deselect 
set_view (\ 
     0.261689752,    0.004401172,   -0.965144753,\ 
     0.593401134,   -0.789389372,    0.157295302,\ 
    -0.761181295,   -0.613876283,   -0.209186524,\ 
     0.000000000,    0.000000000, -113.639129639,\ 
    20.062999725,   48.997001648,   21.891000748,\ 
    85.909431458,  141.368804932,    0.000000000 ) 
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